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ABSTRACT 
Metabolic syndrome (MetS) is the collective term for the interrelated abnormalities 
associated with obesity. Features of MetS promote a variety of chronic diseases that are amongst 
humanity’s most pressing public-health problems. MetS is increasingly appreciated to be 
associated with chronic inflammation driven by an imbalance of host immune cells and expression 
of pro-inflammatory cytokines. While numerous genetic factors influence the development of 
MetS, the increased incidence of this disorder occurring amidst changes in food production and 
dietary habits has led to the presumption that diet and the intestinal microbiota is a major 
determinant of MetS. The overall goal of my studies was to investigate this hypothesis. 
First, I sought to identify microbiota-based markers that might predict diet-induced obesity. 
Targeted and untargeted approaches were utilized including 16S rRNA gene amplicon sequencing 
for microbiome profiling and a TMT-based multiplexed mass spectrometry approach for analysis 
of the fecal metaproteome. Notably, we show that the fecal metaproteome appears to be a 
promising candidate for distinguishing differential responses to high-fat diets (HFD) and provides 
insight into potential mechanisms regarding the host-microbiota interactions mediating response 
to HFD exposure and highlights putative biomarkers for predicting obesity. 
Next, I explored gut-bacterial derived activators of innate-immune signaling as key drivers 
of adipose inflammation and insulin resistance that results from HFD. Hence, another goal of this 
study was to examine how ablation of gut microbiota influenced HFD-induced inflammation 
utilizing three approaches to alter microbiota; antibiotics, germ-free mice, and Altered Schaedler 
Flora mice. We described HFD–induced, microbiota-dependent changes in immune cell 
populations in adipose tissue that associated with pro-inflammatory gene expression and features 
of MetS. 
Lastly, I sought to ameliorate the inflammation that promotes MetS. One common feature 
of inflammation-associated microbiotas is increased levels of flagellin believed to cause intestinal 
inflammation due to flagellin’s ability to activate pro-inflammatory gene expression. Hence, I 
hypothesize that boosting levels of flagellin-specific IgA may help regulate flagellated bacteria 
and, protect against development of intestinal inflammation. Herein, we describe that 
administration of purified flagellin elicits a robust anti-flagellin fecal IgA response that reshapes 
microbiota composition, reduces flagellin expression, and protects against experimental colitis and 
MetS. 
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1 
1 INTRODUCTION 
Metabolic syndrome, medically defined as a cluster of conditions including hypertension, 
hyperglycemia, dyslipidemia, and hypoalphalipoproteinemia, is closely related to obesity and 
affects 34% of Americans leading to 1 in 5 deaths1. One notable theme of research in the past 
decade is the growing appreciation for the state of chronic, low-grade inflammation observed in 
adipose tissue during obesity and its link to insulin resistance and type 2 diabetes mellitus2-5. Even 
with this appreciation, there remain many questions surrounding the link between the immune 
system and metabolic diseases, including the alterations in a number of immune cells associated 
with the chronic, low-grade inflammatory state of obesity6, 7. 
The link between obesity and metabolic disease has been an extensively studied subject 
and countless mechanism have been defined since it’s relationship was originally observed by Dr. 
Jean Vague in 19478. Contributions to the enigmatic relationship between obesity and metabolic 
disease has elucidated that obesity is not an isolated event, but rather affects a wide array of host 
physiology, including energy homeostasis and immunoregulation9. Of interest in the past few 
decades is the involvement of the intestinal microbiota in host homeostasis and disease, and 
conversely, there is growing interest in how obesity may affect the host microbiota10. While 
changes in host physiology is appreciated to contribute to immune system activation, leading to 
inflammation and disease perpetuation11, the extent of intestinal microbiota involvement in 
affecting the host immune system remains to be elucidated. 
 
1.1 Metabolic Syndrome and Host Immunity 
Metabolic syndrome is increasingly appreciated to be associated with chronic low-grade 
inflammation driven by an imbalance of host pro-inflammatory and anti-inflammatory immune 
2 
cells and the expression of anti-inflammatory cytokines. Previous literature has shown that obesity 
results in accumulation of B cells and autoreactive immunoglobulin G (IgG) in visceral adipose 
tissue, as well as increases in Th1 and CD8+ T cells that correlate to decreases in Treg’s12. This 
abnormality in adaptive leukocytes is hypothesized to contribute to the observed chronic, low-
grade inflammation. However, obesity goes beyond the adipose tissue and affects nearly every 
organ, with a common theme being insulin resistance and immune dysregulation13, 14. 
Adipose. As previously highlight, adipose tissue inflammation has been established as an 
important factor in the etiology of insulin resistance. Immune regulation of the adipose tissue is 
also highly important in maintaining homeostasis. Macrophages are perhaps one of the most 
extensively studied immune cell involved in the propagation insulin resistance during obesity. In 
2003, two articles demonstrated for the first time, macrophage accumulation in white adipose 
tissue (WAT) and identified it to be the cause of elevated inflammatory cytokines, thus correlating 
macrophages with insulin resistance and disease perpetuation15, 16. Macrophages show broad 
heterogeneity and function depending on their biological microenvironment. Under normal 
conditions, the adipose tissue of lean mice is shown to comprise of approximately 10% 
macrophages, predominated by the anti-inflammatory M2 (CD11c-) phenotype17-19. During 
obesity, storage of excess triacylglycerol in adipose tissues results in hypertrophy of adipocyte 
morphology and altered release of adipokines and cytokines, leading to Ly6chi monocytes 
recruitment to adipose tissue and polarization to an M1 (CD11c+) phenotype20, 21. This increase in 
M1 macrophages cause an upregulation of pro-inflammatory factors that coincides with down 
regulation of anti-inflammatory cytokines by M2 macrophages and establishes the chronic, low-
grade inflammatory microenvironment. During metabolic homeostasis, eosinophils maintain the 
M2 macrophages population 22, indeed, in experiments using obese mice, it has been observed that 
3 
there is a reduction in the number of eosinophils and M2 macrophages23. Neutrophils have been 
shown to rapidly infiltrate adipose tissue, as soon as 3 days of HFD and levels remain high for up 
to 90 days of HFD. Adipose tissue neutrophils (ATNs) produce pro-inflammatory cytokines and 
chemokines that lead to macrophage infiltration24, 25. Obesity has also shown accumulation of 
human CD11c+CD1c+ and mouse CD11chighF4/80low dendritic cells in adipose tissue26.  
SI/Colon. Central to investigating the role of the microbiota in inducing alterations in the 
immune system are the small and large intestine, as they have direct interactions with the 
microbiota. As such, previous literature has shown changes in their immune environment during 
obesity. Intestinal eosinophils roles in promoting epithelial repair and barrier function during 
homeostasis, but have been shown to be depleted during DIO27. During inflammatory events, 
neutrophils recruit other immune cells and facilitate mucosal healing, however, excessive 
recruitment during diseases such as colitis can cause mucosal injury28. Excessive leukocytes 
recruitment is also caused by increased intestinal permeability, a hallmark of obesity, which 
induces inflammation in response to the increased translocation of bacteria and bacterial products 
across the epithelium. From these events, neutrophils infiltrate the mucosa and produce 
inflammatory cytokines such as calprotectin, lactoferrin, and elastase29. In addition, literature 
shows an induction of the pro-inflammatory cytokine macrophage migration inhibitory factor 
(MIF) correlating to increase IFN-g and NFkB signaling in multiple subtypes and an induction of 
recruited Ly6Chi monocytes to differentiate into inflammatory dendritic cells in the colon30, 31.  
Spleen. Despite being the epicenter of the immune response, not much has been described 
about the spleen in terms of immune cell changes during obesity. Work by Altunkaynak et al. 
showed in 2007 eosinophilic aggregations and lipid accumulations in the sinusoids of the spleen 
in HFD-fed rats32. Indeed, neutrophils infiltrate into the spleen during infection but they are not 
4 
extensively described in context of obesity33. Additionally, Teixeira et al. demonstrated a small 
neutrophil increase in the spleen during colitis and HFD, but were dramatically increased in groups 
with colitis + HFD34.  
 
1.2 Metabolic Syndrome and the Intestinal Microbiota 
Evidence of microbiome involvement in obesity and metabolic disease is clearly 
demonstrated in studies showing that germ-free (GF) mice on high-fat diet (HFD) gain less weight, 
experience lower inflammation, and are protected against insulin resistance compared to their 
conventionally raised controls35. This mouse model of diet-induced obesity (DIO) also showed a 
drastic aberration in the normal microbiota population, particularly an increase in Firmicutes and 
a decrease in Bacteroidetes, and an altered expression of microbial products36. These microbial 
products are highly immunogenic and can contribute to the chronic, low-grade inflammation 
observed during obesity, a phenomenon extensively described in literature29, 37. Briefly, HFD 
induces changes in the gene expression of tight junction proteins of gut epithelial cells, namely the 
reduction in zonula occludens-1 (ZO-1), claudin, and occludin proteins, thus allowing for easier 
translocation of microbial products that go on to activating various components of the immune 
system and inducing inflammation38.  
Meanwhile, the mechanisms that control recruitment and differentiation of myeloid subsets 
during obesity are not well understood. One possible factor of this phenomenon is the intestinal 
microbiota composition. Significant changes in the intestinal microbiota composition and gene 
expression are observed in obese patients and mice models, and previous work has shown the 
intestinal microbiota can affect various components of the host immune system, such as obesity-
related microbiota reducing Th17 cells in the lamina propria39. The role of pattern recognition 
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receptor (PRR) have been demonstrated in studies showing that HFD-fed TLR4KO mice are 
protected against insulin resistance40. Coincidentally, LPS has been identified as a microbial 
molecule affecting M1 polarization and it has been documented that there are elevated serum LPS 
levels in obese individuals and rodents41, however, the direct correlation that increased LPS levels 
drive M1 polarization has yet to be shown, especially in obese models. Targeting and modulating 
the Gram-negative, LPS-producing population of the intestinal microbiome to reduce the 
inflammatory response remains in the realm of possible targets of insulin resistance treatments. 
Studies have shown weight loss results in lowered ATMs and inflammatory markers42, 43.  
 
1.3 Specific Aims of the Study   
My broad hypothesis is that the gut microbiota and its products are pivotal determinants of 
myeloid cell alterations during obesity. More specifically, I hypothesize that the gut microbiota 
may predispose individuals to obesity, and its products also drives and perpetuates inflammation 
exacerbating metabolic disease during obesity. Accordingly, I also hypothesize that finding a 
strategy to maintain the intestinal microbiota may be an approach in treating obesity and metabolic 
syndrome. This hypothesizes will be investigated by the following specific aims: 
Specific Aim 1: Examine the microbiota determinants of obesity. 
Specific Aim 2: Explore the role of the microbiota in driving adipose inflammation. 
Specific Aim 3: Investigate a strategy to prevent bacterial translocation and subsequent 
disease.  
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2 ASSOCIATIONS OF THE FECAL MICROBIAL PROTEOME COMPOSITION 
AND THE PRONESS TO DIET-INDUCED OBESITY 
2.1 Abstract 
Consumption of refined high-fat, low-fiber diets promotes development of obesity and its 
associated consequences. While genetics play an important role in dictating susceptibility to such 
obesogenic diets, mice with nearly uniform genetics exhibit marked heterogeneity in their extent 
of obesity in response to such diets. This suggests non-genetic determinants play a role in diet-
induced obesity. Hence, we sought to identify parameters that predict, and/or correlate with, 
development of obesity in response to an obesogenic diet. We assayed behavior, metabolic 
parameters, inflammatory markers/cytokines, microbiota composition, and the fecal 
metaproteome, in a cohort of mice (n=50) prior to, and the 8 weeks following, administration of 
an obesogenic high-fat low-fiber diet. Neither behavioral testing nor quantitation of inflammatory 
markers broadly predicted severity of diet-induced obesity.  Although, the small subset of mice 
that exhibited basal elevations in serum IL-6 (n=5) were among the more obese mice in the cohort. 
While fecal microbiota composition changed markedly in response to the obesogenic diet, it lacked 
the ability to predict which mice were relative prone or resistant to obesity. In contrast, fecal 
metaproteome analysis revealed functional and taxonomic differences among the proteins 
associated with proneness to obesity. Targeted interrogation of microbiota composition data 
successfully validated the taxonomic differences seen in the metaproteome. While future work will 
be needed to determine the breadth of applicability of these associations to other cohorts of animals 
and humans, this study nonetheless highlights the potential power of gut microbial proteins to 
predict and perhaps impact development of obesity. 
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2.2 Introduction 
Obesity is an emerging 21st century epidemic. Obesity, and the disease states it drives, 
including type 2 diabetes, cardiovascular disease, and liver disease threaten to overwhelm 
healthcare systems44. Thus, obesity is a contemporary medical concern that poses a grave public 
health crisis in dire need of a solution. The increased incidence in obesity is thought to have been 
driven by broad societal changes that have resulted in reduced physical activity and increased 
availability of palatable low-cost energy-rich foods45. Yet the extent to which individuals develop 
obesity in such an environment is highly heterogeneous. Variations in individual genetics 
contribute to, but are insufficient to fully explain, such heterogeneity. For example, studies 
characterizing weight-discordant monozygotic twins has shown that individuals with shared 
environmental, physical activity, and genetic factors display heterogeneity in adiposity46. 
Similarly, rat-based studies show marked heterogeneity in weight gain and adiposity in response 
to obesogenic diets even when using highly inbred animals in a well-controlled environment47, 48. 
Better understanding non-genetic factors that influence proneness to obesity might aid the 
identification of individuals at-risk for development of obesity and can yield modifiable factors to 
ameliorate this disease state.  
A number of factors that are at least partially independent of genetics are proposed to 
influence proneness to diet-induced obesity (DIO). One potential central nexus of such factors is 
inflammation, impacting metabolic signaling pathways including insulin and leptin49, which have 
well-established roles in feeding behavior. Inflammation is also suggested to promote behavioral 
patterns such as anxiety-like and anti-social behaviors that can impact food consumption50. While 
numerous elements impact inflammation, one increasingly appreciated factor is the gut 
microbiota51-55, which is the collective term for the large diverse community of microorganisms 
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that inhabit the gastrointestinal tract. Indeed, in humans, gut microbiota composition is associated 
with obesity. One way microbiota composition influences metabolic signaling is via 
lipopolysaccharide (LPS), which activates pro-inflammatory signaling via Toll-like receptor 4 
(TLR4) resulting in production of molecules including tumor necrosis factor alpha (TNF-a), and 
interleukin-6 (IL-6). These molecules interfere with leptin and insulin signaling, wherein LPS 
derived from gamma-proteobacteria is a particularly potent activator of TLR456. Another host-
microbiota interaction implicated in inflammation and obesity is the sensing of flagella through 
TLR5, which keeps motile bacteria in-check by a range of mechanisms including production of 
antimicrobial peptides and promoting production of anti-flagella immunoglobulins that help 
regulate the microbiota in the healthy gut57. In addition to its impacts on inflammation, microbiota 
composition is also reported to influence energy harvest from ingested food55, 58. Hence, in light 
of its ability to impact inflammation, metabolism, and behavior, gut microbiota composition might 
provide a means of identifying host proneness to obesity when presented with an obesogenic diet.  
Here, we sought to identify microbiota-based markers that might predict proneness to diet-
induced obesity, specifically exposing mice to a western-style, low-fiber high fat diet (HFD). Both 
targeted and untargeted approaches were utilized including 16S rRNA gene amplicon sequencing 
for microbial community profiling and a Tandem Mass Tag (TMT) based multiplexed mass 
spectrometry (MS) approach for analysis of the fecal metaproteome. Additionally, we measured 
behavior, inflammatory markers, and metabolic parameters. Notably, we show that the fecal 
metaproteome appears to be a promising candidate for distinguishing mice with differential 
responses to obesogenic diets. Collectively, this study provides insight into potential mechanisms 
regarding the host-microbiota interactions mediating response to HFD exposure, and highlights 
putative biomarkers for predicting DIO. 
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2.3 Experimental Procedures 
2.3.1 Mice and high-fat diet administration 
Female, 3-5 week old C57BL/6 mice were purchased from Jackson Laboratory (Bar 
Harbor, ME) and maintained at Georgia State University, Atlanta, Georgia, USA under 
institutionally approved protocol under approved protocols (IACUC # A14033), housed 5 mice 
per cage, were subjected to metabolic monitoring, including behavior analysis and sample 
collection over a 3-week period. During this time, the mice were fed standard grain-based chow 
(GBC), which is comprised of relatively unrefined ingredients. The cohort of mice was then 
switched to a diet composed of 60% kcal from fat (Research Diet, D12492) for 8 weeks. Mice 
were then euthanized, and colon length, colon weight, spleen weight and adipose weight were 
measured. Serum, feces, and organs were collected for downstream analysis. 
 
2.3.2 Fecal metaproteome data acquisition 
Fecal samples were measured out to ~0.2 g and suspended in 10 mL of ice-cold, sterilized 
TBS. A 20 µM vacuum, steriflip (Milipore) filter was used to remove particulate from the samples. 
Cells were pelleted through centrifugation at 4000 rpm for 10 min. Next, cells were lysed in 2 mL 
of buffer containing 75 mM NaCl (Sigma), 3% sodium dodecyl sulfate (SDS, Fisher), 1 mM NaF 
(Sigma), 1 mM beta-glycerophosphate (Sigma), 1 mM sodium orhtovanadate (Sigma), 10 mM 
sodium pyrophosphate (Sigma), 1 mM phenylmethylsulfonyl fluoride (PMSF, Sigma), and 1X 
Complete Mini EDTA free protease inhibitors (Roche) in 50 mM HEPES (Sigma), pH 8.559. An 
equal volume of 8M Urea in 50 mM HEPES, pH 8.5 was added to each sample. Cell lysis was 
achieved through two 10-second intervals of probe sonication at 25% amplitude. Proteins were 
then reduced with dithiothreitol (DTT, Sigma), alkylated through iodoacetamide (Sigma), and 
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quenched as previously described60. Proteins were then precipitated via chloroform-methanol 
precipitation and protein pellets were dried61. Protein pellets were re-suspended in 1M urea in 50 
mM HEPES, pH 8.5 and digested overnight at room temperature with LysC (Wako)62. A second, 
6-hour digestion using trypsin at 37 ºC was performed and the reaction was stopped through 
addition of 10% trifluoroacetic acid (TFA, Pierce). Samples were then desalted through C18 Sep-
Paks (Waters) and eluted with a 40% and 80% Acetonitrile solution containing 0.5 % Acetic 
Acid63. Concentration of desalted peptides was determined with a BCA assay (Thermo Scientific). 
50 µg aliquots of each sample were dried in a speed-vac, additional bridge channels consisting of 
25 µg from each sample were created and 50 µg aliquots of this solution were used in duplicate 
per TMT 10-plex (Thermo Scientific) as previously described64. These bridge channels were used 
to control for labeling efficiency, inter-run variation, mixing errors and the heterogeneity present 
in each sample65. Each sample or bridge channel was resuspended in 30% dry acetonitrile in 200 
mM HEPES, pH 8.5 for TMT labeling with 7 µL of the appropriate TMT reagent66. Reagents 126 
and 131 (Thermo Scientific) were used to bridge between mass spec runs. Remaining reagents 
were used to label samples in random order. Labeling was carried out for 1 hour at room 
temperature, and quenched by adding 8 µL of 5% hydroxylamine (Sigma). Labeled samples were 
acidified by adding 50 µL of 1% TFA. After TMT labeling, each 10-plex experiment was 
combined and desalted through C18 Sep-Paks and dried in a speed-vac. Each 10-plex experiment 
was fractionated using a High pH Reversed-Phase Peptide Fractionation Kit (Pierce) per 
manufacturer instructions.  All LC-MS2/MS3 experiments were carried out on an Orbitrap Fusion 
(Thermo Fisher Scientific) with an in-line Easy-nLC 1000 (Thermo Fisher Scientific) and chilled 
autosampler. Separation and acquisition settings were as previously defined67. 
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2.3.3 Metaproteome data processing 
Data was processed using Proteome Discoverer 2.1 (Thermo Fisher Scientific). MS2 data 
was searched against a catalog of mouse gut genes68 (accessed 02/12/2017) containing 2,569,907 
entries along side the Uniprot mouse proteome (www.uniprot.org, access date 11/14/2016) which 
contained 53,374 entries. The Sequest searching algorithm69 was used to align spectra to database 
peptides. A precursor mass tolerance of 50 ppm70, 71 was specified and 0.6 Da tolerance for MS2 
fragments. Included in the search parameters was static modification of TMT 10-plex tags on 
lysine and peptide n-termini (+229.162932 Da), carbamidomethylation of cysteines (+57.02146 
Da), and variable oxidation of methionine (+15.99492 Da). The search parameters included trypsin 
as the enzyme used to generate peptides with a maximum of 2 missed cleavages permitted. A two-
step database search method was utilized72 wherein proteins identified in either the forward or 
reverse database were included in a second search containing 14,368 entries from the original 
mouse gut gene catalog, and annotations derived from this database were used for downstream 
analysis of microbial proteins68. A peptide and protein false discovery rate of 1% was enforced 
using a reverse database search strategy73-75.  
TMT reporter ion intensities were extracted from MS3 spectra for quantitative analysis and 
signal-to-noise ratios were used for quantitation. Additional stringent filtering was used removing 
any moderate confidence peptide spectral matches (PSMs), or ambiguous PSM assignments. 
Additionally, any peptides with a spectral interference above 25% were removed, as well as any 
peptides with an average signal to noise ratio less than 10. Normalization occurred as previously 
described67. Briefly, relative abundances are normalized first to the pooled standards for each 
protein and then to the median signal across the pooled standard. An average of these 
normalizations was used for the next step. To account for slight differences in amounts of protein 
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labeled, these values were then normalized to the median of the entire dataset and reported as final 
normalized summed signal-to-noise ratios per protein per sample.  
 
2.3.4 Behavioral analysis 
Three weeks after arrival in the animal facilities, behavior in the open field and in the home 
cage was assessed in a counter-balanced fashion over the course of two days. Behavioral testing 
occurred within the last 4 h of the light and quiescent phase and was conducted under illumination 
of overhead white lighting (between 300-400 lux). Open field arenas were cleaned with 70% 
ethanol between trials, and home cage bedding was changed after each trial. Behavioral tests were 
videotape using a Sony camcorder for later analysis by The Observer version XT11 (Noldus 
Information Technology Inc., Wageningen, The Netherlands). An experiment blinded as to the 
treatment conditions scored behavioral tests in the Observer.  
 
2.3.5  Open Field Test 
Locomotor behavior was assessed in a 43.2 X 43.2 X 30.5cm (WxLxH) Plexiglas arena 
(Med Associates, Inc., St. Albans, VT) containing 2 arrays of infrared transmitters strips (16 beams 
each) located on the bottom of the arena (in the X and Y plane). The center zone of the arena was 
defined as square containing the center 8 beams (e.g., beams 4-12) in the X and Y plane. Each 
mouse was placed into the arena with its nose facing the wall and allowed to freely investigate for 
10 min. The total distance traveled, the total time spent in the center of the arena, and circling 
behaviors, which are defined as movements below a preset ambulatory threshold, were calculated 
by Activity Monitor (Med Associates, Inc.) on a computer connected to the open field arenas. 
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2.3.6 Home Cage Behavior 
Mice were placed into a clean housing cage containing 2 cm deep Alpha-dri bedding 
(Shepherd Specialty Paper, Fibercore, Cleveland, OH, USA) and video recorded for 10 min. An 
experimenter blinded as to condition scored the occurrence and duration of i) the time spent 
walking, as defined by locomotion along the bottom of the enclosure, around the arena, ii) 
grooming, as defined by stroking or scratching the face of body iii) digging, as defined as using 
the fore- or hind paws to displace  the bedding, and iv) the rears, as defined by standing on the 
hind legs with either the forepaws unsupported or when the forepaws were supported by the walls 
of the enclosure, were quantified using the Observer.  
 
2.3.7 Fasting blood glucose measurement and body composition measurement. 
For fasting blood glucose tolerance test, mice were fasted for 5 hours, and baseline blood 
glucose were measured by using a Nova Max plus Glucose meter and expressed in mg/dL. 
Measurement of percent fat mass and lean mass was performed via MRI (Bruker MiniSpec) at day 
0, prior to diet treatment, and day 28 and 56, after diet treatment. 
 
2.3.8 Fecal sample preparation for immunoglobulin quantification. 
Fecal sample preparation of enzyme-linked immunosorbent assay (ELISA) has been 
previously described76. 100 mg of fecal pellets were homogenized in 3 mL of collection media 
consisting of 0.05 mg soybean trypsin inhibitor per ml of a 3:1 mixture of 1X PBS and 0.1 M 
EDTA, pH 7.4. Following centrifugation at 1800 rpm for 10 minutes, the supernatant was 
centrifuged again at 14,000 rpm for 15 minutes at 4°C, and final supernatant was collected and 
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stored with 20% glycerol and 2 mM phenylmethylsulfonyl fluoride (Sigma, P-7626) at -20°C until 
analysis. 
 
2.3.9 Fecal and serum anti-flagellin IgA/IgG 
Quantification of anti-flagellin- specific IgA and IgG has been previously described77-79. 
Briefly, 96-well microtiter plates (Costar, Corning, New York) were coated with 100 ng/well of 
laboratory-made flagellin in 9.6 pH bicarbonate buffer overnight at 4° C. Serum samples from 
mice were then applied either pure or at a 1:100 dilution for 1 hour at 37° C. After incubation and 
washing, the wells were incubated with either horseradish peroxidase-linked anti-mouse IgG (GE 
Healthcare Life Sciences, Pittsburgh, Pennsylvania) or horseradish peroxidase-linked anti-IgA 
(Southern Biotech, Birmingham, Alabama). Quantification of immunoglobulin was then 
developed by the addition of 3,3’,5,5’-Tetramethylbenzidine and the optical density was calculated 
by the difference between readings at 450nm and 540nm.  
 
2.3.10 Fecal Lcn-2 quantification 
As previously described80, frozen fecal samples were reconstituted in PBS containing 0.1% 
Tween 20 at 100 mg/ml and vortexed for 20 min. The homogenate was then centrifuged at 12,000 
rpm for 10 min at 4°C. Clear supernatants were collected and stored at −20°C until analysis. Lcn-
2 levels were measured in the supernatants using Duoset murine Lcn-2 ELISA kit (R&D Systems, 
Minneapolis, MN). 
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2.3.11 Myeloperoxidase quantification 
Tissue samples were homogenized in 100 mg/mL of 0.5% hexadecyltrimethylammonium 
bromide (Sigma, St. Louis, MO) in 50 mM PBS, pH 6.0, as previously described80. Following 3 
cycles of freeze-thaw at -80°C and 37°C, samples were sonicated and centrifuged at 14,000 rpm 
for 15 min at 4°C. Supernatants were stored at −20°C until analysis. Myeloperoxidase (MPO) was 
assayed in the supernatant by adding 1 mg/mL of dianisidine dihydrochloride (Sigma, St. Louis, 
MO) and 5×10−4% H2O2 and the change in optical density measured at 450 nm. 
 
2.3.12 Serum CXCL1 and IL-6 quantification 
Serum chemokine (C-X-C motif) ligand 1 (CXCL1) and Interleukin-6 (IL-6) 
concentrations were determined using Duoset cytokine ELISA kits (R&D Systems, Minneapolis, 
MN) according to manufacturer’s instructions80. 
 
2.3.13 Fecal flagellin and lipopolysaccharide load quantification 
We quantified flagellin and lipopolysaccharide (LPS) as previously described using human 
embryonic kidney (HEK)-Blue-mTLR5 and HEK-BluemTLR4 cells, respectively (Invivogen, San 
Diego, California, USA)81, 82. We resuspended fecal material in PBS to a final concentration of 
100 mg/mL and homogenized for 10 s using a Mini-Beadbeater-24 without the addition of beads 
to avoid bacteria disruption. We then centrifuged the samples at 8000 g for 2 min, serially diluted 
the resulting supernatant, and applied to mammalian cells. Purified E. coli flagellin and LPS 
(Sigma, St Louis, Missouri, USA) were used for standard curve determination using HEK-Blue-
mTLR5 and HEK-Blue-mTLR4 cells, respectively. After 24 h of stimulation, we applied cell 
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culture supernatant to QUANTI-Blue medium (Invivogen, San Diego, California, USA) and 
measured alkaline phosphatase activity at 620 nm after 30 min. 
 
2.3.14 Microbiota analysis by 16S rRNA gene sequencing using Illumina MiSeq technology 
16S rRNA gene amplification and sequencing were done using the Illumina MiSeq 
technology following the protocol of Earth Microbiome Project with their modifications to the 
MOBIO PowerSoil DNA Isolation Kit procedure for extracting DNA 
(www.earthmicrobiome.org/emp-standard-protocols). Bulk DNA were extracted from frozen 
extruded feces using a PowerSoil-htp kit from MoBio Laboratories (Carlsbad, California, USA) 
with mechanical disruption (bead-beating). The 16S rRNA genes, region V4, were PCR amplified 
from each sample using a composite forward primer and a reverse primer containing a unique 12-
base barcode, designed using the Golay error-correcting scheme, which was used to tag PCR 
products from respective samples83. We used the forward primer 515F 5’-
AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTGTGCCAGCMGCCGCGGT 
AA-3’: the italicized sequence is the 5’ Illumina adapter B, the bold sequence is the primer pad, 
the italicized and bold sequence is the primer linker and the underlined sequence is the conserved 
bacterial primer 515F. The reverse primer 806R used was 5’-
CAAGCAGAAGACGGCATACGAGAT XXXXXXXXXXXX AGTCAGTCAG CCGGACTACH
VGGGTWTCTAAT-3’: the italicized sequence is the 3’ reverse complement sequence of Illumina 
adapter, the 12 X sequence is the golay barcode, the bold sequence is the primer pad, the italicized 
and bold sequence is the primer linker and the underlined sequence is the conserved bacterial 
primer 806R. PCR reactions consisted of Hot Master PCR mix (Five Prime), 0.2 µM of each 
primer, 10-100 ng template, and reaction conditions were 3 min at 95°C, followed by 30 cycles of 
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45 s at 95°C, 60s at 50°C and 90 s at 72°C on a Biorad thermocycler. Four independent PCRs were 
performed for each sample, combined, purified with Ampure magnetic purification beads 
(Agencourt), and products were visualized by gel electrophoresis. Products were then quantified 
(BIOTEK Fluorescence Spectrophotometer) using Quant-iT PicoGreen dsDNA assay. A master 
DNA pool was generated from the purified products in equimolar ratios. The pooled products were 
quantified using Quant-iT PicoGreen dsDNA assay and then sequenced using an Illumina MiSeq 
sequencer (paired-end reads, 2 × 250 bp) at Cornell University, Ithaca. 
 
2.3.15 16S rRNA gene sequence analysis 
Forward and reverse Illumina reads were joined using the fastq-join method84, 85, sequences 
were demultiplexed, quality filtered using Quantitative Insights Into Microbial Ecology (QIIME, 
version 1.8.0) software package86. QIIME default parameters were used for quality filtering (reads 
truncated at first low-quality base and excluded if: (1) there were more than three consecutive low 
quality base calls (2), less than 75% of read length was consecutive high quality base calls (3), at 
least one uncalled base was present (4), more than 1.5 errors were present in the bar code (5), any 
Phred qualities were below 20, or (6) the length was less than 75 bases). Sequences were clustered 
to operational taxonomic units (OTUs) using UCLUST algorithm87 with a 97% threshold of 
pairwise identity (without the creation of new clusters with sequences that do not match the 
reference sequences), and taxonomically classified using the Greengenes reference database 
13_888. A single representative sequence for each OTU was aligned and a phylogenetic tree was 
built using FastTree89. The phylogenetic tree was used for computing the unweighted UniFrac 
distances between samples90, 91, rarefaction were performed and used to compare abundances of 
OTUs across samples. Principal coordinates analysis (PCoA) plots were used to assess the 
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variation between experimental group (beta diversity). Alpha diversity curves were determined for 
all samples using the determination of the number of observed species. LEfSE (LDA Effect Size) 
was used to investigate bacterial members that drive differences between groups92. Unprocessed 
sequencing data are deposited in the European Nucleotide Archive under accession number 
PRJEB33328. 
 
2.3.16 Study design 
The overall study included 50 mice which were followed longitudinally for monitoring of 
weight gain and other measures. The sample size was determined for statistical power based on 
previous publications47, 48 and experience. The metaproteome analysis included four mice with the 
highest weight gain and the lowest weight gain. These samples sizes were determined to be 
sufficient based on previous reports of strong differences in related animal models with similar 
sample sizes 93.  
 
2.3.17 Metaproteome analysis 
Metaproteome analysis was performed using python (version 3.5) and records are available 
online (https://github.com/rhmills/High-Fat_Diet_Metaproteomics_analysis). Extra files 
associated with the analysis within the notebooks are deposited as supplementary files in the 
MassIVE (https://massive.ucsd.edu) repository for this study (Study ID: MSV000083891). All 
analysis was performed on the proteins identified in both TMT 10-plex experiment. Qiime2, 
version 2019.1 (https://qiime2.org/), was used for principle coordinates analysis through the 
command “qiime diversity core-metrics” as well as for determining significance of beta-diversity 
clustering through the command “qiime diversity beta-group-significance”. K-means clustering 
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was performed through Morpheus (https://software.broadinstitute.org/morpheus). Enriched and 
depleted proteins were determined by π–score, which accounts for both fold change and p-value94. 
A statistical cutoff for highly ranked associations was set to |π| > 1 (α ~ 0.05), which provided an 
adequate number of proteins for functional and taxonomic assessment95 while maintaining a 
moderate stringincy. Volcano plots were visualized using GraphPad Prism (version 7.0b). Mouse 
protein gene functional enrichment analysis was performed using DAVID96, with all mouse 
proteins identified as a background list. The python package, Seaborn (version 0.9.0) was used for 
boxplots, swarmplots, and catplots. Statistical analysis between groups within the boxplots was 
performed using ANOVA with Dunnett corrected p-values through GraphPad Prism (version 
7.0b). 
 
2.3.18 Statistical analysis 
Significance was determined using unpaired two-tailed t-test or linear regression analysis 
(GraphPad Prism software, version 6.01). Differences were noted as significant *p≤0.05 for t-test 
or linear regression analysis. For clustering analyzing on principal coordinate plots, categories 
were compared and statistical significance of clustering was determined via Permanova97. 
 
2.4 Results 
2.4.1 Stratification and characterization of mice prone, or resistant, to HFD-induced 
metabolic syndrome.  
The primary goal of this study was to elucidate factors that predict and possibly govern, 
susceptibility to developing obesity in response to administration of an obesogenic diet. Hence, 
we designed a prospective study wherein 50, 3-week old female C57BL/6 mice, housed 5 mice 
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per cage, were subjected to metabolic monitoring, including behavior analysis and sample 
collection over a 3-week period. During this time, the mice were fed standard grain-based chow 
(GBC), which is comprised of relatively unrefined ingredients. The cohort of mice was then 
switched to a diet compositionally low in fiber (5%) and high in fat (35% by mass, 60% by 
calories), herein referred to as an obesogenic diet or high-fat diet (HFD) for an 8-week period. 
Prior to, during and after administration of the high-fat diet, sample collection and monitoring was 
performed as outlined in Fig. 2.6-1A. In accord with our previous rodent-based studies48, the extent 
of obesity following the obesogenic diet was quite heterogeneous with many mice weighing 
between 20-25 grams, which is the approximate weight of age-matched GBC-fed mice of this 
strain/gender. In contrast, some mice appeared to dramatically gain weight over the course of the 
experiment with final weights over 30 grams. Therefore, based on their final body weight, mice 
were stratified into tertiles as being prone, intermediate, or relatively resistant to being obese 
following exposure to an obesogenic diet (Fig. 2.6-1B). First, we examined if mice prone or 
resistant to DIO clustered within cages but did not observe a distribution pattern to support this 
possibility (Fig. 2.6-1C). Nor were these groupings significantly related to the initial weight of the 
mice (Fig. 2.6-1D). The total weight gain over the period of exposure to the obesogenic diet for 
resistant mice was about 40%. This observation is approximately the expected age-related weight 
gain of GBC-fed mice during this period, while prone mice increased in weight by about 70% 
during this period (Fig. 2.6-1E). Fat mass, as determined by magnetic resonance imaging (MRI), 
prior to, during, or at the end of exposure to HFD, was highly correlated with body weight within 
the cohort (Fig. 2.6-1F). Accordingly, post-euthanasia weight of the periovarian fat pad, which 
has classically been used to assess adiposity in mice correlated closely (r2 = 0.8229) with final 
body weights confirming our stratifications reflected degree of adiposity (Fig. 2.6-1G). Final body 
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weights were also correlated with fasting glucose concentration (r2 = 0.2218), suggesting mice that 
were prone to diet-induced obesity were also prone to its downstream consequences (Fig. 2.6-1H). 
Lastly, in light of the appreciation that low-grade intestinal inflammation can promote adiposity 
and its consequences, we measured weight/length ratio of the colon98, 99. This measurement was 
also correlated with final body weight (r2 = 0.2781; Fig. 2.6-1I), supporting the notion that the 
obese mice were in a state of low-grade gut inflammation. 
 
2.4.2 Associations of inflammatory markers/mediators and proneness to obesity. 
Low-grade inflammation is reported to associate with and promote obesity99, 100. 
Accordingly, we investigated levels of pro-inflammatory mediators to determine if they might 
mark mice that would be prone to becoming obese following exposure to an obesogenic diet. 
Hence, we measured levels of fecal lipocalin-2 (Lcn-2), which is a broadly dynamic marker of gut 
inflammation80. Levels of fecal Lcn-2 did not correlate with final body weights when measured 14 
days prior (r2 = 0.0156) to exposure or 4 weeks after the initiation of the diet (r2 = 0.0074; Fig. 
2.6-2A, B). Additionally, the levels of serum pro-inflammatory cytokines CXCL1 and IL-6 when 
measured 7 days prior to administration of the obesogenic diet were also not correlated to final 
body weight (r2 = 0.0177, 0.022 respectively, Fig. 2.6-2C, D). However, 4 of the 5 mice that 
displayed detectable serum IL-6 at this time point were in the top tertile of obesity following the 
diet suggesting the subset of mice displaying this parameter might be more prone to DIO. To 
further investigate this subset of mice, we tested for differences within various parameters 
associated with diet-induced obesity between the subsets of mice with or without detectable IL-6. 
At day -7, several of these parameters were consistent with the possibility that detection of IL-6 
can discriminate high or low responders, but ultimately, none reached statistical significance (Fig. 
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2.7-1). Nevertheless, such elevations in IL-6 were not maintained when assayed after 8-weeks of 
diet (Fig. 2.6-2E). Other findings supporting the notion that obesity is associated with low-grade 
inflammation included a modest correlation after 8-weeks of diet between body weights and 
CXCL1, which is a chemokine expressed by many cell types and often used as a general serum 
marker of low-grade inflammation (r2 = 0.0352, Fig. 2.6-2F). In contrast, there was no correlation 
between final body weights and levels of intestinal myeloperoxidase (MPO), which is a widely 
used marker of classic inflammation in the intestine101 (Fig. 2.6-2G). 
Gut bacterial components, flagellin and lipopolysaccharide (LPS), are well known for their 
inflammatory properties102, 103. Fecal levels of each were measured 3 weeks prior to administration 
of the obesogenic diet with neither correlating with final body weight (Fig. 2.6-2H, I). However, 
flagellin, but not LPS, were modestly correlated with final body weight when measured 4 weeks 
following initiation of the obesogenic diet (r2 = 0.0984, 0.0151 respectively, Fig. 2.6-2J, K). 
Moreover, there was a correlation in levels of anti-flagellin antibodies at the time of diet 
administration (for IgG but not IgA) and 8 weeks following exposure to obesogenic diet (Fig. 2.6-
2L-O). Levels of anti-flagellin antibodies likely reflect exposure of the immune system to this 
molecule, which can be influenced by both levels of flagellin in the gut, bacterial-epithelial 
distance, and intestinal permeability78, 104. Together, these studies did not reveal a reliable 
predictive marker of proneness to diet-induced obesity but suggest exposure to bacterial products, 
such as flagellin, might have some predictive power. 
 
2.4.3 Quantitative measures of behavior did not predict obesity proneness 
The gut-brain axis is increasingly appreciated to play a role in the pathogenesis of many 
neurological and metabolic diseases105. Hence, we investigated the extent to which certain 
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behavioral parameters are able to predict proneness to weight gain. Compulsive behavior and 
activity level were measured in a home cage behavior test, and time spent digging (Fig. 2.7-2A), 
time spent grooming (Fig. 2.7-2B), and total distance travelled (Fig. 2.7-2C) were quantified. 
Additionally, anxiety-like behavior was assessed using the open field test, represented by time 
spent in the center zone (Fig. 2.7-2D) and distance travelled in the center (Fig. 2.7-2E) of the open 
field arena. Ultimately, none of these measures had a significant ability to predict extent of obesity 
in response to the obesogenic diet.  
 
2.4.4 Impact of DIO on fecal metaproteome. 
We next turned to a contemporary metaproteomics approach to study the fecal protein 
composition of our cohort of mice. While administration of an obesogenic diet is well known to 
rapidly alter gut microbiota species composition106, whether it might also impact the fecal 
metaproteome, let alone whether the fecal metaproteome might predict responsiveness to such a 
diet, has not been described. While metaproteomic analysis presents the challenges of 
discriminating host and bacterial proteins from potentially millions of proteins, the field is an area 
of rapid growth currently developing standard methodology107. 
To this end, we applied our recently developed TMT-based metaproteomic methods95, in 
combination with a two-step database search method72 on feces from mice that developed the 
highest and lowest degree of obesity (n= 4 mice per condition). Our analysis included specimens 
collected before (day 0) and after 56 days of exposure to the obesogenic diet. The final data 
included quantitation of 13,975 proteins of which 1,108 were derived from mice.  
For a broad scale perspective of the data, an unsupervised Principle Coordinates analysis 
of the metaproteome data using the Bray-Curtis distance metric exhibited clear separation of 
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samples before and after diet administration, reflecting a dramatic impact of the obesogenic diet 
on the overall fecal metaproteome (Fig. 2.6-3A). This analysis also exhibited clustering at the 56 
day time point discriminating high and low response to diet (Permanova pseudo-F = 1.99, p = 
0.058). Using K-means clustering, we identified 6 protein clusters, some of which were associated 
with increased representation of particular taxa and functions (Fig. 2.6-3B). These groupings 
include Group 4, which appeared to show an increased presence of Clostridiales and lipid transport 
and metabolism proteins in high responder mice after exposure to HFD (Fig. 2.6-3B). These 
groupings provide putative taxonomic associations to the functional differences observed before 
and after administration of HFD.  
Comparing all samples before and after HFD exposure made evident that there were 
widespread changes in the fecal metaproteome. By using a statistical ranking method accounting 
for both fold change and t-test p-values, π-score 94, we observed that 58% (3670/6311) of proteins 
displayed a high level of association to diet exposure (|π| > 1, Fig. 2.6-3C). The proteins associated 
with the dietary intervention contained large differences in their taxonomic and functional 
annotations. Taxonomic differences included a larger portion of proteins from Clostridiales and 
Bacteroidales before HFD exposure while a large portion (~40%) of proteins enriched after 8-
weeks exposure were derived from Lactobacillales (Fig. 2.6-3D).  
Functional categorization of the proteins associated to the dietary intervention was 
performed through the Evolutionary Genealogy of Genes: Non-supervised Orthologous Groups 
(eggNOG) database.  These studies revealed a very strong association between proteins related to 
motility and HFD exposure as expression levels of 141 proteins were reduced following exposure 
to HFD with only 3 proteins increased after HFD, resulting in a 32-fold difference (Fig. 2.6-3E).  
In accord, we note that, on average, levels of fecal flagellin decreased by about 5-fold when 
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measured 21 days preceding or 4 weeks following administration of the obesogenic diet (Fig. 2.6-
2H, J). Further, when subsetting all 680 flagellin proteins from the metaproteome dataset, we 
observed statistically significant decreases in abundance for both high and low responding mice 
(p < 0.0001; Fig. 2.7-3A). Functional assessment of the proteins enriched after HFD exposure 
resulted in weaker associations, the strongest of which was a 1.5-fold increased representation of 
Transcription proteins (Fig. 2.6-3E).  
 
2.4.5 Functional and taxonomic characterization of fecal metaproteome in low- and high-
responder mice fed the obesogenic diet. 
We next focused the analysis on discovering patterns in the fecal metaproteome that might 
have preceded or accompanied degree of responsiveness to the obesogenic diet. Toward this end, 
we examined the broad-scale functional composition of each sample’s metaproteome through the 
eggNOG database. This revealed only modest variance amongst the samples (Fig. 2.6-4A). In 
contrast, viewing the composition of taxonomic orders in this manner revealed differences, both 
preceding and following diet exposure, that associated with a high- and low-response to the diet 
(Fig. 2.6-4B). There were 424 highly ranked proteins (|π| > 1) differentiating high and low 
responders at the initial time point (Fig. 2.6-4C). These proteins had large differences in their 
taxonomic origins with all proteins distinguishing the low responders belonging to Clostridiales 
while high responders had over 50% of proteins derived from Bacteroidales and Lactobacillales 
(Fig. 2.6-4D). Functionally, the proteins distinguishing high responders had a 14-fold enrichment 
in “Posttranslational modification, protein turnover, and chaperones” proteins, and a 5.6-fold 
enrichment in “Cell motility” proteins (Fig. 2.6-4E). Many of the posttranslational modification, 
protein turnover, and chaperone proteins with the largest differences between high and low 
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responders were chaperone proteins (Fig. 2.7-3B), a potential indication of a microbial stress 
response. The increased representation of cell motility proteins was a result of a subset of flagella, 
mostly derived from the order Clostridiales, that were significantly increased in high responders 
(p < 0.0001; Fig. 2.7-3C).   
We also noted unique sets of carbohydrate metabolism and transport proteins differentially 
expressed at the initial time point. High responders had increased expression of Bacteroidale 
metabolism proteins including isomerases, kinases and aldolases, while Clostridiales uniquely had 
an increased expression of sugar transporters within low responders (Fig. 2.7-3D). This could be 
an indication of unique energy harvesting capacities in the microbiome present before the onset of 
HFD treatment55. 
 In the samples collected following administration of the obesogenic diet, there were 970 
proteins distinguishing high and low responders (Fig. 2.6-4F). In contrast to proteins 
discriminating responses at the onset of HFD exposure, the proteins corresponding to high 
response were derived entirely from Clostridiales, while nearly 60% of proteins in low responders 
were derived from Lactobacillales (Fig. 2.6-4G). Changes following the obesogenic diet 
associated with a high response to the diet included an 11-fold increased representation of lipid 
transport and metabolism proteins (Fig. 2.6-4H). It is possible that the increase in lipid metabolism 
proteins from Clostridiales mediates more efficient harvesting of energy from lipids in high 
responding mice.  
 
2.4.6 Analysis of fecal mouse proteins. 
In addition to analyzing microbial proteins from the metaproteome, we next subset the data 
to determine associations within the fecal mouse proteome. In total, 699 host proteins were 
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quantified within all samples and therefore included in the statistical analyses. A large portion 
(77%) of mouse proteins were strongly influenced by HFD exposure, and 92% of those proteins 
were increased after HFD (Fig. 2.6-5A). Using DAVID functional enrichment96, we identified 
significant (Bonferroni adjusted p-values < 0.05) enrichment of digestion and myosin proteins 
before HFD treatment and mitochondrial proteins after HFD. Notably, myosin proteins occupied 
6 of the top 10 proteins associated with the initial samples (Fig. 2.6-5B). Phosphorylated myosin 
light chains have previously been linked to intestinal permeability after HFD exposure48. Thus, 
our observed decrease in heavy chain myosin proteins may be related to changes in intestinal 
permeability. In regards to the increase of mitochondrial proteins, it was shown that HFD results 
in mitochondrial dysfunction108, and our data likely reflects this phenomena. 
We next looked for mouse fecal proteins that might discriminate high and low responders 
prior to HFD administration. Here, 109 mouse proteins strongly differed between the groups, all 
of which were enriched in the DIO prone mice (Fig. 2.6-5C). Of these proteins, 40 (37%) were 
related to immunoglobulin. This strong enrichment for immunoglobulin genes was confirmed 
through DAVID, which showed a significant, 3-fold enrichment (Bonferroni p-value = 7.0E-11) 
for Immunoglobulin V-set proteins. This enrichment of immunoglobulin variable domains was 
also illustrated in the top 20 proteins associated with a heightened response to HFD (Fig. 2.6-5D). 
These findings further illustrate the link between low-grade inflammation and DIO, as this is a 
potential indication of increased immune activity in high responder mice, before administration of 
HFD. 
Applying the same analysis to samples collected after 8-weeks exposure to HFD also 
revealed interesting insight into proneness to HFD exposure. After the dietary intervention, 63 
mouse proteins were highly ranked in their ability to discriminate between high and low 
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responders. All but two of these proteins were enriched within the low responders (Fig. 2.6-5E). 
Functional analysis showed a significant 6-fold enrichment (Bonferroni p-value = 4.0E-8) for 
keratin within the proteins enriched within low responders. This increase of keratin could be an 
indication of greater colonic stress109 in low responders at the final time point. High responders at 
this time had several immunoglobulin proteins within the top discriminatory proteins, though most 
were only modestly associated (Fig. 2.6-5F). Of note, many of the immunoglobulin proteins were 
among the strongest discriminatory proteins in high responders at both the initial and final day.  
 
2.4.7 Analysis of microbiota composition vs. proneness and severity to DIO. 
Lastly, we examined the potential of fecal microbiota composition, as analyzed by 16S 
rRNA gene sequencing to identify and/or reflect proneness to DIO. Visualization of fecal 
microbiota composition of all 50 mice at all time points by unweighted UniFrac revealed the 
expected dramatic difference in microbiota composition before and following administration of 
the obesogenic diet (p = 0.001; Fig. 2.6-6A). This analysis also showed clear, but much more 
modest differences between the 5 and 8-week post-dietary change time points (Fig. 2.6-6A). In 
contrast, using this approach to examine differences in beta diversity did not identify differences 
in microbiota composition in high or low-responders either prior to (p = 0.977; Fig. 2.6-6B), or 
following administration of the obesogenic diet (p = 0.323; Fig. 2.6-6C). Rather, in accord with 
other diets, 8-week administration of the diet, which provided mice an additional 8 weeks to share 
their microbiota with their cage-mates, we observed strong cage clustering of microbiota 
compositions (p = 0.001; Fig. 2.6-6D). Nonetheless, levels of alpha-diversity, prior to 
administration of the obesogenic diet were moderately but significantly correlated (r2 = 0.0873, p 
= 0.0394) with final body weights (Fig. 2.6-6E) suggesting that microbial community structure 
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had some ability to predict proneness to DIO. An analogous but not significant trend was observed 
8-weeks post-dietary change (Fig. 2.6-6F). 
That overall assessment of microbiota composition lacked ability to identify high- and low- 
responder mice does not preclude the possibility that select OTUs might provide such power. 
Hence, we selected specific OTUs whose abundance was enriched or depleted at time 0 in the mice 
that developed the greatest degree of obesity in response to HFD. This yielded an array of bacterial 
groups, those of which had the ten lowest p values represented here, Fig. 2.7-4. However, 
determining whether these differences are reproducible and/or biologically significant will require 
further experimentation. Additionally, we examined the ability of bacterial candidates generated 
by the metaproteomic analysis to predict (day 0), or reflect (day 56), proneness to the obesogenic 
diet. Of the 12 taxa analyzed in the day 0, 3 groups showed correlations predicted by the proteomic 
analysis with p values lower than 0.1 (Fig. 2.6-6G-I) while 9 did not (Fig. 2.7-5 A-I). Regarding 
the taxa proteomic analysis identified as correlating with extent of obesity in the day 56 samples, 
2 taxa correlated as determined with p-values lower than 0.1 (Fig. 2.6-6J-K) while the 10 others 
analyzed did not meet this criteria (Fig. 2.7-6 A-J). Thus, overall, while development of 
approaches to predict proneness to obesity via analysis of the fecal proteome and/or microbiome 
remains a work in progress, these findings support its potential to contribute to such 
prognostications. 
 
2.5 Discussion 
The goal of this study was to improve understanding of non-genetic determinants of DIO, 
focusing on parameters that might be impacted by gut microbiota, which is known to play a role 
in dictating severity of DIO. As obesity is promoted by low-grade, systemic inflammation, which 
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can be driven by exposure to microbiota products48, we hypothesized that inflammatory and 
microbial factors might impact behavior and/or metabolism and thereby predict the extent of DIO 
displayed by individual hosts. However, the behavioral measures of general activity and anxiety 
in 6 – 8 week old mice were not predictive of susceptibility to HFD-induced obesity while the 
inflammatory markers IL-6, MPO, CXCL1, and LCN-2 showed only very limited ability in 
discriminating proneness to DIO when measured before, during, or after administration of HFD. 
From a microbial perspective, research has shown roles for LPS and flagellin in inflammation and 
obesity57, 110, 111. However, while measuring flagellin levels showed promise for predicting weight 
after administration of HFD, it was less successful prior to administration. Our results revealed 
new evidence of host-microbial interactions underlying differential weight gain. 
To find microbial factors that may correlate to DIO, we next turned to an untargeted 
metaproteomic approach. Our results confirm prior research showing large shifts in the overall 
structure of the metaproteome after administering HFD93. These broad shifts seem to be driven by 
proteins derived from Clostridiales and Bacteroidales, which decreased upon exposure to HFD, 
while the composition of Lactobacillales proteins expands. Interestingly, this difference was not 
observable in our analysis of the microbiota by 16S sequencing. One possible explanation is the 
known discrepency between genomic and proteomic technologies95 which is supported by the 
notion that differences in protein abundance are not directly associated with species composition 
due to complex regulatory processes. However, other DNA sequence-based studies have also 
shown significant alterations in Clostridiales and Bacteroidales upon exposure to HFD48, 112, 
further suggesting a role for these taxonomies in HFD response. 
Functionally, the most striking shift with HFD was the decreased abundance of flagella 
after administration of HFD. Flagellin proteins can be targeted in several ways by the host, 
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including the release of anti-flagellin IgA and anti-flagellin IgG. The levels of Anti-flagellin IgA 
are anti-correlated with total flagellin load, and are a key mechanism for down regulating motility-
related genes57. While the overall levels of anti-flagellin IgG and IgA in general did not 
significantly correlate with the obesogenic outcomes, we did see a distinct immune signature 
within the fecal proteome of the high responder mice. This data may suggest that the mice that 
gain the most weight have a baseline immune reaction occurring before treatment. Possible 
antigens of this immune reaction were also identified from the metaproteome data including a 
subset of flagellin proteins that effectively discriminate high and low responders. However, as 
most of the identified immunoglobulin subunit regions could be a result of either IgA or IgV113, it 
is not clear whether this potential reaction is mediated through TLR5, NOD-like receptor 4, or 
other mechanisms110. 
Taxonomic differences were also consistent with the idea that flagellin directed 
immunoglobulin may be shaping the gut of high responders before the onset of HFD. The majority 
of flagellin proteins identified were derived from Clostridiales, and Bacteroidales do not contain 
flagella 114. Here we observed a dominance of Clostridiales proteins enriched in low responders at 
the onset while Bacteroidales proteins contained a large portion of the high responder 
metaproteome. If the observed immunoglobulin proteins from the metaproteome were targeting 
flagella, it may be expected that the portion of Clostridiales proteins would be shifted in favor of 
Bacteroidales. 
In total, our results suggest the ability of host and microbial proteomics to discern subjects 
particularly prone to developing DIO. Our results indicated significant metaproteome differences 
between high and low responding mice despite the limited number of samples analyzed. In 
addition, the taxonomic origins and functional roles of these discriminatory proteins suggested 
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new evidence that host-microbiota interactions may be underlying proneness to DIO. While larger 
studies are needed to confirm our results, the fecal metaproteome appears to be a promising tool 
for identifying hosts at risk of weight gain upon exposure to an obesogenic diet. 
 
2.6 Figures and Legends 
 
Figure 2.6-1. Stratification and characterization of mice prone, or resistant, to HFD-
induced metabolic syndrome. 
(A) 3-5-week old, female C57BL/6 mice were purchased from The Jackson Laboratory and 
housed for three weeks before high-fat diet administration in order to favor microbiota 
stabilization. Subsequently, animals were treated with high-fat diet (60% kcal from fat) for 8 
weeks. Serum collection occurred on days -7, 0, and 56. Body weight measurements occurred prior 
to every flagellin administration. Fecal collection occurred on days -21 and -7, then every other 
week starting on day 0. (B) Mice were identified as low, intermediate, or high responders based 
on if their final body weight fell within the first, second, or third tertile, respectively. (C) Final 
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Figure	1.		Stratification	and	characterization	of	mice	prone	or	resistant	to	HFD-
induced	metabolic	syndrome.
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body weights of mice by cage. (D) Initial weights of mice. (E) Body weights were measured weekly 
and expressed as relative values, day 0 (pre high-fat diet treatment) being defined as 100%. Final 
body weights were correlated to (F) fat mass by MRI, (G) epididymal adipose weight, (H) day 56 
fasting blood glucose, and (I) colon weight/length ratio. Data are the means +/- S.E.M. (N=50). 
Significance was determined using linear regression analysis (*p≤0.05). 
 
 
Figure 2.6-2. Associations of inflammatory markers/mediators and proneness to obesity. 
Final body weights correlated to fecal lipocalin-2 at (A) day -14 and (B) 28, analyzed 
using ELISA kits. Additionally, final body weights were correlated to serum cytokines CXCL1 and 
IL-6 at (C-D) day -7 and (E-F) day 56, analyzed using ELISA kits. Final body weights were also 
correlated to (G) colonic myeloperoxidase levels, as well as, fecal flagellin and lipopolysaccharide 
at (H-I) day -21 and (J-K) day 28 using HEK 293 cells expressing mTLR5 or mTLR4 measuring 
bioactive flagellin and lipopolysaccharide, respectively. Serum anti-flagellin IgG and IgA were 
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Figure	2.	Associations	of	inflammatory	markers/mediators	and	proneness	to	
obesity.
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also quantified using ELISA techniques at days 0 (L-M) and 56 (N-O). (N=50). Significance was 
determined using linear regression analysis (*p≤0.005). 
 
 
Figure 2.6-3. Impact of DIO on fecal metaproteome. 
(A) Principal coordinates analysis (PCoA) of  metaproteome data using the Bray-Curtis 
distance metric (B) Protein relative abundance heatmap. Samples are clustered by 1-Pearson 
correlation and proteins are grouped using KMeans clustering. Relative abundances per protein 
are colored on a spectrum with red as row maxima and blue as row minima. Functional and 
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taxonomic bias within each KMeans cluster is displayed on the right. (C) Volcano plot of 
metaproteome response to HFD. Fold change and t-test significance of each protein are plotted. 
Overall significance was set at |π-score| > 1. (D) Taxonomic composition of significant proteins. 
(E) Functional bias in significant proteins. Compositions of eggNOG annotations between 
proteins enriched in the final and initial time points were compared and the log ratio of high 
abundance categories (>10 proteins) is shown. Sample names in (A-B) are annotated H for High 
Responder, L for Low Responder, then I for Initial time point, F for Final time point, with 1,2, 3, 
or 4 for replicate number. 
 
 
Figure 2.6-4. Functional and taxonomic characterization of fecal metaproteome in low- 
and high-responder mice fed the obesogenic diet. 
(A) Functional Composition. (B) Taxonomic Composition. (C-E) Comparison of 
significant proteins from high and low responders at the initial timepoint. (C) Volcano plot 
displaying the fold change and t-test significance of each protein in the metaproteome. 
Significance was set at |π-score| > 1. (D) Taxonomic composition of significant proteins. (E) 
Barplots demonstrating the functional bias in significant proteins. Compositions of eggNOG 
annotations were compared between high and low responders and the log ratios of the high 
abundance categories (>10 proteins) are shown. (F-H) Comparison of significant proteins from 
high and low responders at the final timepoint. Same analysis as (C-E) for the final time point. 
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Sample names in (A-B) are annotated H for High Responder, L for Low Responder, then I for 
Initial time point, F for Final time point, with 1,2, 3, or 4 for replicate number. 
 
 
Figure 2.6-5. Analysis of mouse fecal proteome. 
After sub-setting the mouse derived proteins from the metaproteome data, differentially 
expressed proteins were determined using a statistical cut-off of |π-score| > 1. Volcano plots are 
shown demonstrating the log2 fold change (x-axis) and log10 p-value (y-axis) for (A) differences 
between final and initial samples, (C) differences between high and low responders and the initial 
time point, and (E) differences between high and low responders at the final time point. The π-
score of the most significant proteins from each analysis are shown below each volcano plot in 
bar plots (B,D,F). 
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Figure 2.6-6. Analysis of microbiota composition vs. proneness and severity to DIO. 
Fecal microbiota composition was analyzed using Illumina sequencing of the V4 region of 
16S rRNA genes. Principal coordinates analysis (PCoA) was performed using the unweighted 
UniFrac distance metric (A) over the course of HFD administration, (B) day 0, (C-D) day 56. 
Final body weights were correlated to alpha diversity at (E) day 0 and (F) day 56. Final body 
weights were correlated to bacterial groups found at the start of HFD administration: (G) 
Clostridiales, (H) Coriobacteriaceae, and (I) Bacteroidales. Final body weights were also 
correlated to bacterial groups found at the end of HFD administration: (J) Bacteroidales and (K) 
Campylobacterales. (N=50). In A-D, categories were compared and statistical significance of 
clustering were determined via Permanova. In E-K, significance was determined using linear 
regression analysis (*p≤0.005) 
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Figure	6.	Analysis	of	microbiota	composition	vs.	proneness	and	severity	to	DIO.
p	=	0.001
p	=	0.001
p	=	0.323
p	=	0.977
38 
2.7 Supplemental Figures and Legends 
 
Figure 2.7-1. Comparison of metabolic parameters in mice with detectable vs. 
undetectable basal serum IL-6. 
CXCL1 at day -7 were quantified using ELISA kits. Mice with detectable or undetectable 
levels of CXCL1 were compared by (A) final body weight, (B) body weight growth by percent, (C) 
perigonadal adipose tissue, (D) spleen weight, and (E) fat mass measured by MRI. Data are the 
means +/- S.E.M. (N=45, 5 for Untectable IL-6 and Detectable IL-6 groups, respectively). 
Significance was determined using t-test. In B + E, statistical significance was determined by t-
test at day 56. 
 
 
Figure 2.7-2. Lack of association of behavioral measurements with proneness to DIO. 
Final body weights were correlated to home cage behaviors represented by (A) time spent 
digging, (B) time spent grooming, and (C) total distance travelled. Final body weights were also 
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correlated to open field behaviors represented by (D) time spent in the center and (E) distance 
travelled in the center. (N=50). Significance was determined using linear regression analysis. 
 
 
Figure 2.7-3. Subsets of the metaproteome differentially expressed in DIO. 
(A) A combined boxplot and swarmplot displaying the relative abundances of all flagella 
proteins. (B) A combined swarm plot and boxplot showing the relative abundance of a subset of 
posttranslational modification and chaperone proteins significantly enriched (π-score > 1) in high 
responders at the initial time point. (C) A combined boxplot and swarmplot displaying the relative 
abundances of a subset of flagella proteins significantly enriched in high responder mice at the 
initial timepoint (π-score > 1). (D) Swarm plots subset by taxonomic order showing the relative 
abundance of carbohydrate transport and metabolism proteins differentially expressed (|π-score| > 
1) between high and low responders at the initial time point. In A and C: ns, not significant; ****, 
ANOVA p-value < 0.0001. 
 
 
Supplemental	Figure	3.	Subsets	of	the	metaproteome differentially	expressed	in	
DIO.
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Figure 2.7-4. Display of OTUs enriched or depleted in DIO prone and resistant mice. 
Fecal microbiota composition was analyzed using Illumina sequencing of the V4 region of 
16S rRNA genes. 10 OTU with lowest uncorrected p value in t-test between low and high 
responders represented here. Data are the means +/- S.E.M. (N=50). Significance was determined 
using t-test. 
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Supplemental	Figure	4.	Display	of	OTUs	enriched	or	depleted	at	in	DIO	prone	and	
resistant	mice.	
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Figure 2.7-5. Analysis of microbiota composition vs. development of DIO. 
Fecal microbiota composition was analyzed using Illumina sequencing of the V4 region of 
16S rRNA genes. Final body weights were correlated to bacterial groups found at the start of HFD 
administration: (A) Lactobacillales, (B) Erysipelotrichale, (C) Verrucomicrobiales, (D) 
Bacillales, (E) Actinobacteria, (F) Desulfovibrionales, (G) Enterobacteriales, (H) 
Burkholderiales, and (I) Campylobacterales. (N=50). Significance was determined using linear 
regression analysis. 
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Figure 2.7-6. Association of microbiota composition vs. severity of DIO. 
Fecal microbiota composition was analyzed using Illumina sequencing of the V4 region of 
16S rRNA genes. Final body weights were correlated to bacterial groups found at the end of HFD 
administration: (A) Burkholderiales, (B) Erysipelotrichale, (C) Clostridiales, (D) Lactobacillales, 
(E) Coriobacteriaceae, (F) Verrucomicrobiales, (G) Bacillales, (H) Actinobacteria, (I) 
Desulfovibrionales, and (J) Enterobacteriales. (N=50). Significance was determined using linear 
regression analysis. 
 
2.8 Disclosures 
2.8.1 Availability of data and materials.  
All data generated or analyzed during this study are included in this published article. 
Metaproteomic data is available through massive (massive.ucsd.edu) under study ID 
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MSV000083891. The data is also available through Proteome Xchange 
(http://proteomecentral.proteomexchange.org) under the study ID PXD014128. 
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3 “WESTERN-DIET”-INDUCED ADIPOSE INFLAMMATION REQUIRES A 
COMPLEX GUT MICROBIOTA 
3.1 Abstract 
Consumption of a western-style high-fat diet (WSD or HFD) induces adiposity and visceral 
adipose inflammation characterized by elevations in M1:M2 macrophage ratio and pro-
inflammatory cytokine expression, both of which contribute to WSD-induced metabolic 
syndrome. WSD-induced adipose inflammation might result from ER stress in lipid-overloaded 
adipocytes and/or dissemination of gut bacterial products resulting in activation of innate immune 
signaling. Our goal was to investigate the role of the gut microbiota, and its detection by innate 
immune signaling pathways, in WSD-induced adipose inflammation. Mice were fed grain-based 
chow or WSD for 8 weeks, metabolically assessed, and intestinal and adipose tissue analyzed by 
flow cytometry and qRT-PCR. Microbiota was ablated via antibiotics and use of gnotobiotic mice 
that completely lacked microbiota (germ-free mice; GF) or had a minimal pathobiont-free 
microbiota (Altered Schaedler Flora; ASF). Innate immune signaling was ablated by genetic 
deletion of TLR signaling adaptor MyD88. Ablation of microbiota via antibiotic, GF, or ASF 
approaches did not significantly impact WSD-induced adiposity but yet dramatically reduced 
WSD-induced adipose inflammation as assessed by macrophage populations and cytokine 
expression. Microbiota ablation also prevented colonic neutrophil and CD103- dendritic cell 
infiltration. Such reduced indices of inflammation correlated with protection against WSD-
induced dysglycemia, hypercholesterolemia, and liver dysfunction. Genetic deletion of MyD88 
phenocopied ablation of microbiota. These results indicate that adipose inflammation, and some 
aspects of metabolic syndrome, are not purely a consequence of diet-induced adiposity per se but, 
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rather, may require disturbance of intestine-microbiota interactions and subsequent activation of 
innate immunity.  
 
3.2 Introduction 
Metabolic syndrome is the collective term for the inter-related metabolic abnormalities 
associated with obesity. Features of metabolic syndrome, which include insulin resistance, 
dysglycemia, hypercholesterolemia, hypertension, and hepatic steatosis, promote a variety of 
dangerous and costly chronic diseases that are amongst humanity’s most pressing public health 
problems. While numerous genetic factors influence susceptibility to development of metabolic 
syndrome, that the increased incidence of this disorder has occurred amidst stark societal changes 
in food production and dietary habits has led to the general presumption that diet is a major 
determinant of metabolic syndrome. In accordance, in mice, replacement of grain-based chow for 
a low-fiber high-fat diet (HFD), recapitulates many features of metabolic syndrome and, hence 
serves as a useful tractable model to mechanistically study non-genetic determinants of this 
disorder.   
Metabolic syndrome is increasingly appreciated to be associated with, and driven by, 
chronic low-grade inflammation especially in visceral adipose tissue. In particular, metabolic 
syndrome, in humans and mice fed HFD, is associated with a change in macrophage phenotypes 
in visceral adipose tissue, characterized by an increase in classic “pro-inflammatory” M1 
macrophages and a decrease in “anti-inflammatory” M2 macrophages15-19. Such changes correlate 
with, and drive increased adipose expression of pro-inflammatory cytokines and decreased 
expression of anti-inflammatory cytokines. Such adipose inflammation has been proposed to result 
from accumulated lipids within adipocytes causing ER stress that activates intrinsic signaling 
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pathways that result in activation of NF-κB-mediated pro-inflammatory gene expression115. 
Additionally, and/or alternatively, it has been proposed that gut microbiota components might play 
a central role in adipose inflammation. Cani and colleagues found that HFD increases 
dissemination of gut bacterial-derived lipopolysaccharide (LPS) and that direct low-dose systemic 
administration of LPS led to elevations in pro-inflammatory cytokines in adipose tissue gene 
expression and insulin resistance. This suggests that LPS, and perhaps other gut bacterial-derived 
activators of innate immune signaling, might be key drivers of the adipose inflammation and 
insulin resistance that results from HFD100. The general notion that gut microbiota plays a key role 
in driving HFD-induced metabolic syndrome is also supported by reports that germ-free mice are 
protected against various features of metabolic syndrome, including adiposity and dysglycemia35, 
116, although the extent of such microbiota dependence varies markedly amongst the several 
published studies in this area117. Moreover, such studies did not examine adipose inflammation but 
rather attributed the metabolic impacts of microbiota ablation to inflammation-independent 
mechanisms, such as calorie extraction. Furthermore, a general caveat of studies relying on germ-
free mice is that these mice have a variety of immunological abnormalities, which might influence 
responses to inflammatory challenges in general118. Hence, the central goal of this study was to 
examine how ablation of gut microbiota influenced WSD-induced adipose inflammation, 
especially in terms of macrophage polarization thought to play a critical role in driving and 
maintaining the inflammatory state. We utilized three approaches to ablate microbiota; antibiotics, 
germ-free mice, and gnotobiotic mice with a minimal but pathobiont-free microbiota (Altered 
Schaedler Flora; ASF), that confers more normal gut physiology119. Additionally, we examined 
how such microbiota ablation impacted changes in immune cell populations in the colon, where 
the majority of microbiota is localized. We observed that WSD–induced microbiota-dependent 
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changes in immune cell populations in the colon and adipose tissue that associated with adipose 
pro-inflammatory gene expression and some features of metabolic syndrome, albeit not adiposity 
per se.   
 
3.3 Experimental Procedures 
3.3.1 Mice and high-fat diet administration 
Male, 4-week old (Wild Type and MyD88-KO) C57BL/6 mice were purchased from 
Jackson Laboratory (Bar Harbor, ME) and maintained at Georgia State University, Atlanta, 
Georgia, USA under institutionally approved protocols (IACUC # A18006), housed 5 mice per 
cage with ALPHA-dri bedding (Shepherd Specialty Papers) and nestlets (Ancare) and fed ad 
libitum. Mice were fed standard grain-based chow (GBC), which is comprised of relatively 
unrefined ingredients and given 2 weeks to allow for microbiota stabilization. Following, half the 
cohort of mice was then switched to a diet composed of 60% kcal from fat (Research Diet, D12492) 
for 8 weeks, while the remaining half continued on the GBC as a control. For antibiotic treatment, 
two days prior to WSD feeding, mice were administered drinking water containing ampicillin (1 
g/L), vancomycin (0.25 g/L), neomycin (1 g/L), and metronidazole (1 g/L), water supply was 
renewed every 3 days and maintained during WSD feeding. Mice were then euthanized, and body 
weight, colon length, and weights of adipose depots (perigonadal visceral adipose, interscapular 
brown adipose, and posterior subcutaneous adipose), colon, liver, and spleen were measured. 
Serum and organs were collected for downstream analysis.  
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3.3.2 Germ-free and Altered Schaedler flora mice experiments  
C57BL/6 Altered Schaedler flora mice obtained from the Georgia State University-
breeding repository and germ-free mice purchased from Taconic Biosciences (Rensselaer, NY) 
were housed in a Tecniplast IsoCage Bioexclusion System in our germ-free facility. Mice were 
fed a modified rodent diet with 60 kcal% fat and 1.5x Vitamin Mix irradiated twice with 10-20 
kGy γ-irradiation (Research Diet, D12492-1.5Vi) for 8 weeks. Samples were then collected as 
described previously.  
 
3.3.3 Serum panel analyses 
Mice were bled after 15-hour fasting and hemolysis-free serum was collected using serum 
separating tubes (BD Biosciences). Serum cholesterol, AST and ALT were measured by using 
biochemical kits from Randox Laboratories (Kearneysville, WV). 
 
3.3.4 RNA extraction and quantitative RT-PCR (qRT-PCR) 
Total RNA extraction was performed as previously described120. Briefly, RNAs were 
extracted using TRIzol reagent (Invitrogen, 15-596-026), with RNAs from adipose tissue purified 
using the RNeasy Mini Kit (Qiagen, 74106). Purified RNAs were reverse transcribed and qPCR 
was performed in duplicates using an iTaq Universal SYBR® Green One-Step Kit (Bio-Rad, 
1725151) on a CFX96 apparatus (Bio-Rad, Hercules, CA). The sense and antisense 
oligonucleotides used were, respectively, the following: 36B4 5’- TCCAGGCTTTGGGCATCA-
3’ and 5’-TCTTTATCAGCTGCACATCACTCAGA-3’, CXCL1 5’-
ACTGCACCCAAACCGAAGTC-3’ and 5’-TGGGGACACCTTTTAGCATCTT-3’, IL-6 5’-
GTGGCTAAGGACCAAGACCA-3’ and 5’-GGTTTGCCGAGTAGATCTCA-3’, TNF-a 5’-
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CGAGTGACAAGCCTGTAGCC-3’ and 5’-CATGCCGTTGGCCAGGA-3’, IL-1b 5’-
TCATGGGATGATGATAACCTGCT-3’ and 5’-CCCATACTTTAGGAAGACACGGATT-3’, 
IL-10 5’-ACCTGGTAGAAGTGATGCCCCAGGCA-3’ and 5’-
CTATGCAGTTGATGAAGATGTCAAA-3’. Results were normalized to the housekeeping 36B4 
gene. Fold-induction was calculated using the Ct method as follows: ΔΔCt = 
(Cttarget gene- Cthousekeeping gene)treatment - (Cttarget gene- Cthousekeeping gene)nontreatment, and the final data were 
derived from 2−ΔΔCT. 
 
3.3.5 Fasting blood glucose 
Mice were fasted for 15 hours during nocturnal cycle, and baseline blood glucose were 
measured by using a Nova Max plus Glucose meter and expressed in mg/dL.  
 
3.3.6 Fecal Microbiota Transplants 
Feces from WSD- or chow-treated mice were suspended in 30% glycerol diluted in PBS 
(1.0 mL) and stored at −80°C81. Germ-free C57BL/6 mice (5 weeks old) purchased from Taconic 
Biosciences (Rensselaer, NY) were orally administered with 200µL of above fecal suspension and 
housed in a Tecniplast IsoCage Bioexclusion System.  
 
3.3.7 Adipose tissue preparation 
Isolation and preparation of stromal vascular cells (SVCs) from the adipose tissue was 
performed as previously described121. Both perigonadal fat pads were digested in 10 mL of 1 
mg/mL of Type IV collagenase buffer in HBSS (w/ Ca2+ and Mg2+) with 0.5% BSA for 20 min at 
37°C. After digestion, EDTA was added to a final concentration of 10 mM and incubated at 37°C 
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for an additional 10 min. SVC were passed through a 100-µm nylon filter and a 40-µm nylon filter, 
respectively, before centrifugation at 500×g for 10 min at 4°C to separate adipocytes from SVCs. 
The adipocyte containing supernatant was removed and the SVC pellet was resuspended in 0.5 mL 
of red blood cell (RBC) lysis buffer and incubated for 5 min at room temperature. Following, 5 
mL of FACS buffer was added to neutralize the RBC lysis buffer. Cells were then pelleted by 
centrifugation at 500×g for 10 min at 4°C before staining for leukocyte surface markers.  
 
3.3.8 Intestinal tissue preparation 
Isolation and preparation of cells from intestinal tissue was performed as previously 
described122. Briefly, colons and small intestines from mice were cut into small 1.0 cm long pieces 
and placed into 20 mL of HBSS with 5% FBS and 2 mM EDTA and incubated with shaking for 
20 min at 37°C. Following, the aliquot was passed through a sieve and the intestinal pieces were 
washed on the sieve with 10 mL of HBSS with 5% FBS. Incubation and wash steps were repeated 
once more before the colon pieces were minced with a small razor. The minced intestines were 
then incubated in 20 mL of HBSS with 5% FBS, 1 mg/mL collagenase type VIII, and 0.1 mg/mL 
DNase I with shaking for 10 min at 37°C. Following incubation, 20 mL of HBSS with 5% FBS 
was added to the cells before vortexing and centrifugation for 10 min at 1500 rpm. Cells were then 
resuspended in HBSS with 5% FBS and pass through a 100 µm filter then a 40 µm cell strainer, 
respectively. Following centrifugation, cells were then stained for leukocyte surface markers.  
 
3.3.9 Splenic tissue preparation 
Following euthanasia, spleens were crushed between two frosted microscope slides and 
added to 5 mL of media RPMI with 10% FBS. Cells were then filtered through a 100 µM filter 
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with an additional 5 mL of RPMI with 10% FBS used to wash the filter. Cells were centrifuged at 
1500 rpm for 5 min and cell pellets were resuspended in 5 mL of RBC lysis buffer and incubated 
at 37°C for 10 min before centrifugation at 1500 rpm for 5 min. Resuspended cells were filtered 
through a 40 µM before another wash step. Following centrifugation, cells were then stained for 
leukocyte surface markers. 
 
3.3.10 Peyer’s Patch (PP) preparation 
Isolation and preparation of cells from intestinal tissue was performed as previously 
described123. Briefly, removed Peyer’s Patches were transferred into 5 mL Dissociation Medium 
(RPMI with 1 mg/mL Collagenase IV, 0.1 mg/mL DNase, and 5% FBS) and incubated for 20 min 
at 37 °C with vigorous shaking. PPs were placed onto a sterile 70 µm nylon mesh cell strainer and 
forcibly grinded into the mesh. EDTA was added to a final concentration of 1 mM to the cell 
suspension and incubated on a rocker for 5 min at room temperature. The cell suspension was 
passed through a second 70 µm cell strainer to remove any remaining cellular aggregates or tissue 
debris. Following, cells were centrifuged for 5 min at 1500 rpm and resulting cell pellets were 
stained for leukocyte surface markers.  
 
3.3.11 Live/dead and leukocyte discrimination 
Following isolation, all cells were washed with 300 µL of cold PBS twice. Cells were then 
resuspended in 100 µL of Alexa 430 NHS ester at working dilution and incubated at 4°C for 20 
min in the dark. Following incubation, cells were washed with FACS buffer (PBS with 1mM 
EDTA and 0.5% BSA) prior to incubation with anti-Mouse CD16/CD32 to block non-specific 
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binding of Fc receptors. Staining cocktails were added to cells as outlined on Supplementary 
Tables 1-5. Lastly, cells were washed three times before fixation by 1% paraformaldehyde.  
 
3.3.12 Flow cytometry data acquisition 
Single stained controls were made using UltraComp eBeads Compensation Beads 
(Invitrogen, 01-2222-41) using manufacturer’s instructions. Data acquisition was performed on a 
BD LSRFortessa, for every sample, 100,000 events were collected in the LiveCD45+ gate and cell 
populations were analyzed on FlowJoTM 10.  
 
3.3.13 Statistical analysis 
Significance was determined using unpaired one-tailed or two-tailed t-test. Significance 
determined by t-test are expressed using their values, with brackets indicating significance p≤0.05, 
or noted as either *p≤0.05, **p≤0.01, ***p≤0.001, or ****p≤0.0001.  
 
3.4 Results 
3.4.1 Characterization of changes in tissue leukocytes in response to diet-induced obesity 
(DIO) 
The central goal of this study was to test the hypothesis that intestinal microbiota plays a 
central role in driving western-style high-fat diet (WSD)-induced alterations in populations of 
leukocytes, especially those in visceral adipose tissue that mediate chronic inflammation and 
promote metabolic syndrome. Hence, we first sought to broadly define changes in leukocyte 
populations induced by an obesogenic diet. C57BL/6J mice (6-week old males) were maintained 
on standard grain-based rodent chow or administered WSD for 8 weeks, at which time they were 
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euthanized and tissues harvested for analysis. Our focus on endpoint assays was designed to enable 
subsequent gnotobiotic approaches utilized below. In accord with previous studies, administration 
of WSD resulted in a marked elevation in body weight (Fig. 3.6-1A), adiposity (Fig. 3.6-1B) and 
fasting blood glucose (Fig. 3.6-1C). Such indices of WSD-induced metabolic syndrome are 
associated with infiltration of, and relative population changes in, visceral adipose tissue 
macrophages. Hence, we first analyzed visceral white adipose tissue by flow cytometry using the 
gating procedure outlined in Figure S1A. Data was collected until 100,000 events was reached in 
the Live/CD45+ gate. For data analysis, cells were gated for appropriate SSC-A/FSC-A and 
singlets. Live CD45+MHCII+ cells were identified as macrophages if they were CD11b+ (or 
F4/80+) and CD64+. From these macrophages, M1 macrophages were identified as CD301-, M2 
macrophages were identified as CD301+ (Fig. 3.7-1A). In accord with previous studies, WSD led 
to an increase in the number of macrophages per gram of adipose tissue (Fig. 3.6-D), as well as an 
increase in the proportion of “pro-inflammatory” M1 macrophages, and a decrease in “anti-
inflammatory” M2 macrophages thus resulting in a 25-fold increase in the M1:M2 ratio in response 
to WSD (Fig. 3.6-1E). These changes were not observed following 4 weeks of WSD-feeding (data 
not shown) and thus we restricted our studies to the 8-week time point, at which we also observed 
a moderate increase in the overall number of adipose dendritic cells per gram of fat (Fig. 3.6-1F), 
driven by an increase in CD11b+CD103- subset of dendritic cells during obesogenic conditions, 
while CD11b-CD103+ dendritic cells were not appreciably impacted (Fig. 3.6-1G). Live 
CD45+MHCII- cells of the adipose tissue were identified as eosinophils if they were Siglec-F+ and 
Ly6-G-, concurrently neutrophils were identified as Siglec-F-Ly6-G+ (Fig. 3.7-1C). In accord with 
previous studies, we also observed a decrease in the adipose eosinophils in response to WSD (Fig. 
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3.6-1H). Lastly, in contrast to some studies, we did not observe an increase in adipose neutrophils 
in response to WSD-feeding (Fig. 3.6-1H).  
We recently reported that WSD induces dramatic morphologic changes in the colon. While 
such impacts appear to be mediated by impacts on epithelial cell proliferation, and primarily 
WSD’s lack of fiber than its fat content per se, they nonetheless are thought to promote WSD-
induced low-grade inflammation and metabolic syndrome124, 125. Thus, we next analyzed the extent 
to which WSD might impact leukocyte populations in the small intestine and/or colon following 
8 weeks of WSD consumption. Live CD45+MHCII+ cells were identified as dendritic cells if they 
were CD11c+ and CD64- and further categorized as either CD103- or CD103+ (Fig. 3.7-1B). We 
observed a modest increase in total colonic dendritic cells, that did not reach statistical significance 
(Fig. 3.6-1I), driven by an increase CD103- dendritic cells and to a lesser extent by CD103+ 
dendritic cells (Fig. 3.6-1J). We did not observe changes in either colonic eosinophil nor 
macrophage populations (Fig. 3.6-1K and 3.7-2A). We also noted a modest trend toward of 
increased colonic neutrophils that seemed worthy of monitoring in subsequent experiments (Fig. 
3.6-1K). WSD induced only modest changes, in fact reductions, in some leukocyte populations in 
the small intestine and Peyer’s Patches (Fig. 3.7-2), while the only observed change in the spleen 
was a moderate increase in inflammatory monocytes (Fig. 3.7-2F); gating procedures detailed in 
Fig. 3.7-1. Altogether, these results indicated that the previously-observed changes in adipose 
macrophages are amongst the most prominent changes in leukocytes induced by this WSD and 
identified less pronounced changes in colonic leukocytes that might contribute to the WSD-
induced low-grade inflammation that promotes metabolic syndrome. 
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3.4.2 Microbiota ablation did not mitigate WSD-induced adiposity but ameliorated features of 
metabolic syndrome.  
Investigation of the extent to which a particular phenotype requires presence of microbiota 
has generally utilized antibiotic or germ-free approaches, both of which have benefits and caveats. 
Concerns with germ-free mice include that they have broadly underdeveloped and dysregulated 
immune systems and are not able to digest, and thus harvest energy from plant-derived complex 
carbohydrates. Thus, a related approach is use of gnotobiotic mice colonized with a highly 
restricted microbiota such as 8 bacterial species known as the Altered Schaedler Flora (ASF), 
which lack the pathobionts that we and others hypothesize drive low-grade inflammation and 
metabolic syndrome but yet have more normal immune and gut physiology119. Hence, we utilized 
these 3 approaches to investigate the extent to which microbiota impact WSD-induced phenotypes. 
Control (i.e. conventional specific pathogen-free) and microbiota-ablated mice were 
maintained on standard chow (autoclaved for GF and ASF mice) or administered WSD (irradiated 
for GF and ASF mice) for 8 weeks (Fig. 3.6-2A), at which time they were euthanized, and 
metabolic and immunologic parameters assayed. Absolute measures of metabolic parameter are 
shown in Figure S3 while relative differences between mice fed chow vs. WSD within each 
microbiota condition are shown in Figure 2. This visualization facilitates evaluation of the extent 
to which microbiota ablation impacted the metabolic effects of WSD and, at least in this case, 
yields similar trends as the non-normalized data. Specifically, microbiota ablation only modestly 
reduced WSD-induced weight gain (Fig. 3.6-2B) and did not reduce WSD-induced increases in 
visceral fat nor other adipose depots (Fig. 3.6-2C-E). However, microbiota ablation protected 
against several indices of metabolic syndrome that otherwise result from WSD. Specifically, the 
extent of WSD-induced dysglycemia was reduced (Fig. 3.6-2F) as were increases in ALT, AST, 
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and serum cholesterol (Fig. 3.6-2G-I). Accordingly, WSD-induced hepatomegaly, which 
correlates well with WSD-induced steatosis was reduced in antibiotic-treated and ASF mice (Fig. 
3.6-2J). Additionally, microbiota ablation prevented WSD-induced morphometric changes that 
reflect low-grade inflammation such as increase in colon weight/length ratio and spleen weight 
(Fig. 3.6-2K-L). Thus, in contrast to some studies, including our on-going studies that used shorter 
WSD exposures, ablation of microbiota did not significantly reduce the extent of adiposity that 
results from an 8-week exposure to WSD but yet ameliorated other aspects of WSD-induced 
metabolic syndrome.    
 
3.4.3 Microbiota ablation reduced WSD-induced changes in adipose and colonic leukocytes  
While, under the conditions used herein, microbiota ablation did not impact extent of 
WSD-induced adiposity, that it ameliorated some aspects of metabolic syndrome led us to 
hypothesize it might reduce the adipose inflammation that is thought to promote this disorder. In 
accord with this hypothesis, ablation of microbiota by all 3 approaches, albeit more clearly for 
ASF and germ-free, markedly reduced the WSD-induced changes in visceral adipose macrophages 
(Fig. 3.6-3A-C). Specifically, microbiota ablation prevented the absolute and relative increase in 
M1 macrophages (Fig. 3.6-3D-E) and reduced the relative, but not absolute decrease in M2 
macrophages (Fig. 3.6-3F-G) thus largely preventing the increase in M1:M2 ratio (Fig. 3.6-3H). 
Additionally, the modest trend of WSD resulting in reduced adipose eosinophils seen in 
conventional mice was not observed in antibiotic-treated and ASF mice (Fig. 3.7-4A-B). In accord 
with the notion that macrophage populations are a key determinant of the overall inflammatory 
tone of visceral adipose tissue, we observed that microbiota ablation largely eliminated WSD-
induced increases in adipose expression of pro-inflammatory cytokines, including CXCL1, TNF-
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a, and IL-1b while increasing expression of IL-10 in antibiotic-treated and germ-free mice (Fig. 
3.6-3I). 
Ablation of microbiota also reduced many of the changes in leukocyte populations 
observed in the colon in response to WSD (Fig. 3.6-4A-C). Specifically, all 3 means of reducing 
gut bacteria reduced the total increase in colonic DC (Fig. 3.6-4D) via preventing increases in 
CD103- DC (Fig. 3.6-4E) without impacting the trend of WSD-induced increases in CD103+ DC 
(Fig. 3.6-4F). Additionally, microbiota ablation prevented the modest increase in colonic 
neutrophils observed in response to WSD (Fig. 3.6-4G) although the extent of these changes, even 
in conventional mice, did not result in significant changes in pro-inflammatory gene expression in 
the colon per se (data not shown). Together, these results indicate that WSD-induced changes in 
leukocytes that mediate inflammation require the presence of a complex microbiota.  
 
3.4.4 Genetic depletion of TLR-signaling adaptor MyD88 phenocopies microbiota ablation in 
response to WSD 
That transplant of microbiota from genetically modified mice that had developed metabolic 
syndrome when consuming standard rodent chow to WT germ-free mice transferred some indices 
of metabolic syndrome indicates that microbiota composition per se rather than the mere presence 
of a complex microbiota is a determinant of metabolic disease99. Hence, we next examined the 
extent to which transplant of microbiota from WSD-fed WT mice to germ-free mice fed chow 
might transplant adipose inflammation and/or other aspects of metabolic syndrome. In accord with 
work from Rabot et al126, we observed that, relative to germ-free mice conventionalized with feces 
from chow-fed mice, transplant of microbiota from WSD-fed mice did not exhibit increased 
adiposity nor other features of metabolic syndrome (Fig 3.7-5A-I). Moreover, transplant of such 
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WSD microbiota did not result any differences in leukocyte populations in adipose tissue or colon 
(Fig 3.7-5J-T). Interestingly, WSD microbiota recipients did exhibit modest, albeit not statistically 
significant elevations in CXCL1 and TNF-a in the adipose tissue, which was counterbalanced by 
a significant increase in IL-10 arguing against the notion that the adipose tissue was in a state of 
low-grade inflammation (Fig. 3.7-5U). Thus, transfer of WSD-derived microbiota alone did not 
recapitulate adipose inflammation or metabolic syndrome.  
We hypothesize that inability to manage microbiota, and pathobionts in particular, as a 
result of WSD’s impact on the colon results in microbiota promoting inflammation via activation 
of innate immune signaling pathways. This hypothesis predicts that absence of the global TLR 
signaling adaptor protein MyD88, which has been observed to protect against some aspects of 
WSD-induced metabolic syndrome, should protect against adipose inflammation. In agreement 
with this notion and other studies, the relative and absolute extent of weight gain and adiposity 
induced by WSD was blunted in MyD88-KO mice (Fig. 3.6-5A-B and 3.7-3L-M). Furthermore, 
absence of MyD88 protected against WSD-induced indices of metabolic syndrome including 
dysglycemia, elevated ALT, and hypercholesterolemia (Fig. 3.6-5C-D and 3.7-3N-O). MyD88-
KO mice were also protected from WSD-induced inflammation as assessed by colon weight-length 
ratio and spleen weight (Fig. 3.6-5E-F and 3.7-3O&Q). Moreover, in response to WSD, MyD88 
did not exhibit adipose inflammation as assessed by changes in leukocyte populations or cytokine 
expression (Fig. 3.6-5G-N). Nor did they exhibit increases in colonic DC or neutrophils (Fig. 3.6-
5O-R). Thus, the absence of MyD88 largely phenocopied microbiota ablation thus supporting our 
hypothesis that WSD-induced adipose inflammation does not result from lipid accumulation per 
se but, rather, is promoted by microbiota or their products activating innate immune signaling 
pathways.   
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3.5 Discussion 
Inflammation of visceral adipose tissue is a central link between obesity and the 
constellation of metabolic abnormalities referred to as metabolic syndrome. Hence, there is great 
interest in understanding mechanisms by which adipose tissue acquires an inflammatory profile 
and how this profile impacts adiposity and other aspects of metabolic syndrome. That excess lipid 
loading can be sufficient to drive pro-inflammatory gene expression provides a plausible 
explanation whereby increased adiposity, by itself, can drive adipose inflammation127. However, 
that adipose inflammation and parameters of metabolic syndrome can also be induced by transplant 
of microbiota with pro-inflammatory features99 or direct administration of LPS100. indicate that 
microbiota is also a plausible determinant of adipose inflammation. Hence, the central goal of this 
study was to investigate the extent to which gut microbiota was necessary for the low-grade 
inflammation, especially in adipose tissue, induced by a western-style high-fat diet (WSD), which 
is thought to model the obesity epidemic that has resulted, in part, from societal changes in dietary 
habits. We utilized 3 approaches of ablating microbiota, all of which yielded a similar pattern of 
results, namely that, microbiota was not essential for WSD-induced adiposity but yet played a 
critical role in adipose inflammation and, consequently, features of metabolic syndrome. 
While our observation that microbiota was not required for WSD-induced adiposity per se 
might seem to contradict some published work in this field, overall, we submit our results are in 
accord with the variety of studies in this field in which some studies observed germ-free mice were 
markedly protected against WSD-induced obesity while others observed similar adiposity in germ-
free and conventional mice117. Some such variance might be accounted for by the array of different 
approaches utilized. For example, Gordon and colleagues compared germ-free mice to 
conventionalized mice, which are prone to obesity, relative to conventional mice116, while studies 
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by Rabot et. al. compared conventional and germ-free mice fed WSD and did not assess impact of 
WSD relative to mice maintained on a control diet35. Yet, we do not submit that such differences 
are sufficient to explain the observed differences in result from various studies, nor do we dispute 
the notion that, in some conditions, ablation of microbiota can protect against WSD-induced 
adiposity. Indeed, we have observed some antibiotic regimens protects against WSD-induced 
adiposity124, 128 while recent experiments in our lab continue to indicate that, in response to a 4-
week WSD treatment, GF and ASF mice exhibit reduced adiposity relative to conventional mice 
(data not shown). However, this study focused on adipose inflammation, particularly that 
characterized by changes in macrophage population, which was not observed in response to 4 
weeks WSD feeding thus precluding this time point herein.  
On the one hand, some consequences of WSD-feeding occur very rapidly. Relative to mice 
fed grain-based chow, WSD induces rapid (within 3 days) reduction of colonic bacterial density, 
marked changes in species composition and a stark reduction in colonocyte proliferation that 
results in marked morphologic changes accompanied by microbiota encroachment124, which we 
propose to drive inflammation and dysglycemia129. On the other hand, more traditional markers of 
inflammation such as elevations in serum cytokines, and leukocyte infiltration have generally only 
been reported in response to longer-term WSD feeding. Some metabolic consequences of WSD 
occur quite rapidly with dysglycemia being present within days of exposure to WSD although 
robust development of metabolic syndrome, including more severe insulin resistance requires 
longer-term exposure to WSD130. Genetic approaches that seek to block leukocyte activation 
indicate that inflammation is dispensable for the rapid changes but critical for long-term insulin 
resistance130. Thus, we conclude that irrespective of whether or not it impacts adiposity per se, 
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ablation of microbiota protects against adipose inflammation, which is a key driver of metabolic 
syndrome.   
That absence of MyD88, which is necessary for generation of pro-inflammatory signaling 
by TLRs (except TLR3) and inflammasome cytokines IL-1b and IL-18, thus making it effectively 
necessary for many aspects of nod-like receptor signaling as well, fully mimicked the protection 
against adipose inflammation that resulted from microbiota ablation suggests a role for bacterial 
products in driving adipose inflammation. The combination of microbiota encroachment amidst 
reduced gut barrier function in response to WSD can be envisaged to result in bacterial products 
or perhaps even bacteria reaching the visceral adipose tissue but we certainly not exclude the 
possibility that adipose inflammation is driven by bacterial-induced cytokines in other tissues that 
then act upon adipocytes. That ASF mice were protected from WSD-induced adipose 
inflammation, and its associated metabolic consequences, underscores that microbiota 
composition, rather than the mere presence of bacteria in the gut is a determinant of susceptibility 
to WSD and, moreover supports the possibility that pathobiont bacteria might be key contributors 
to WSD-induced metabolic syndrome.  
In conclusion, our findings indicate that the mechanism by which WSD-induced obesity 
results in adipose inflammation is dependent on the intestinal microbiota, possibly reflecting a 
deterioration in intestinal-microbiota homeostasis that result in activation of innate immune 
signaling to protect against encroaching and/or translocating bacteria. Should such events occur in 
humans, they might, in part, be a basis for why some obese persons remain relatively metabolically 
healthy while others develop metabolic syndrome and downstream deleterious consequences. 
Moreover, we speculate that irrespective of its impact upon adiposity, restoration of a host-
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microbiota homeostasis through diet, pharmacologic, and/or perhaps pre/pro-biotic approaches 
might be a means to alleviate visceral adipose tissue inflammation and its metabolic consequences.  
 
3.6 Figures and Legends 
 
Figure 3.6-1. Characterization of changes in tissue leukocytes in response to diet-
induced obesity. 
4-week old, male C57BL/6J mice were purchased from The Jackson Laboratory and 
housed for two weeks to favor microbiota stabilization. Subsequently, half of the mice were 
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Figure	1.	Characterization	of	changes	in	tissue	leukocytes	in	response	to	diet-induced	
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switched to a high-fat diet (60% kcal from fat) or continued on a standard grain-based chow as a 
control. Following 8-weeks on a WSD, mice were euthanized for biometric measurements 
represented here: (A) final body weight and (B) visceral adipose weight. Additionally, (C) 15-
hour fasting blood glucose was measured prior to euthanasia. Visceral adipose from the 
epididymitis was analyzed by flow cytometry to quantify: (D) macrophages, (E) M1:M2 
macrophage ratios, (F) dendritic cells, (G) CD11b+CD103- and CD11b-CD103+ dendritic cells 
subsets, (H) eosinophils, and neutrophils. Colon tissue was utilized for flow cytometry to quantify 
as cells per organ: (I) dendritic cells, (J) CD103-/+ dendritic subsets, and (K) eosinophils and 
neutrophils. Data are the means +/- S.E.M. Statistical significance was determined using t-test 
(brackets indicates significance, p<0.05). 
 
 
Figure 3.6-2. Microbiota ablation did not mitigate WSD-induced adiposity but 
ameliorated features of metabolic syndrome. 
(A) 4-week old, male C57BL/6J conventionally-raised mice were purchased from The 
Jackson Laboratory, 4-week old, male C57BL/6 mice possessing an Altered Schaedler flora were 
obtained from the Georgia State University-breeding repository, and 3-5-week old, male C57BL/6 
germ-free mice were purchased from Taconic Biosciences. At Day 0, animals were switched to a 
high-fat diet (60% kcal from fat) for 8 weeks or continued on a standard grain-based chow as a 
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Figure	2.	Microbiota	ablation	did	not	mitigate	WSD-induced	adiposity	but	ameliorated	
features	of	metabolic	syndrome.
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control. An additional group of conventional, C57BL/6J mice were started on an antibiotic 
cocktail 3 days prior to high-fat diet administration and maintained throughout the experiment. At 
day 56, mice were euthanized for tissue collection and biometric measurements, data of WSD-
treated mice represented here is relative to the chow-fed mice of their corresponding groups: (B) 
final body weight, (C) visceral adipose tissue weight, (D) subcutaneous adipose tissue weight, (E) 
brown adipose tissue weight, (F) 15-hour fasting blood glucose, (G) ALT, (H) AST, (I) total serum 
cholesterol, (J) liver weight, (K) colon weight/length ratio, and (L) spleen weight. Data are the 
means +/- S.E.M. Statistical significance was determined using t-test (*p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001, n.s. indicates non-significant). 
 
 
Figure 3.6-3. Microbiota ablation reduces macrophage infiltration and M1 macrophage 
polarization, reducing M1:M2 ratio. 
Visceral adipose tissue from the epididymitis of mice was analyzed utilizing flow cytometry 
to quantify: (A) macrophages and (B) M1 and M2 macrophages subsets. Data of WSD-treated 
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Figure	3.	Microbiota	ablation	reduces	macrophage	infiltration	and	M1	macrophage	
polarization,	reducing	M1:M2	ratio.		
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mice represented here is relative to the chow-fed mice of their corresponding groups: (C) number 
of macrophages per gram of adipose tissue, M1 macrophages as a (D) percent of total 
macrophages and (E) number per gram of adipose tissue, and M2 macrophages as a (F) percent 
of total macrophages and (G) number per gram of adipose tissue. (H) M1:M2 macrophage ratios 
were quantified using percent of M1 and M2 macrophages. Visceral adipose tissue collected at 
euthanasia was also analyzed for (I) cytokines via qRT-PCR. Data are the means +/- S.E.M. Data 
are the means +/- S.E.M. Statistical significance was determined using t-test (*p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001, n.s. indicates non-significant, # indicates limited sample quantity 
prevented use of statistical analysis). 
 
 
Figure 3.6-4. Microbiota ablation reduces dendritic cell alterations and neutrophil cell 
infiltration in the colon. 
Colon tissue was analyzed utilizing flow cytometry to quantify: (A) dendritic cells, (B) 
CD103+/- dendritic cells, and (C) neutrophils. Data of WSD-treated mice represented here is 
relative to the chow-fed mice of their corresponding groups: (D) number of dendritic cells, (E) 
number of CD103- dendritic cells, (F) number of CD103+ dendritic cells, and (G) number of 
neutrophils per colon. Data are the means +/- S.E.M. Data are the means +/- S.E.M. Statistical 
significance was determined using t-test (*p≤0.05, **p≤0.01, n.s. indicates non-significant). 
 
Chow WSD
Conv
Water
Conv
ABX
ASF GF
0.0
0.5
1.5
2.0
2.5
Colon Dendritic Cells
fo
ld
 c
ha
ng
e 
in
 c
el
ls
1
* n.s.n.s.n.s.
Conv
Water
Conv
ABX
ASF GF
0
2
3
Colon CD103 - DCs
fo
ld
 c
ha
ng
e 
in
 c
el
ls
1
** n.s.n.s.n.s.
Conv
Water
Conv
ABX
ASF GF
0
2
3
Colon CD103 + DCs
fo
ld
 c
ha
ng
e 
in
 c
el
ls
1
n.s.n.s. **
Conv
Water
Conv
ABX
ASF GF
0
2
3
Colon Neutrophils
fo
ld
 c
ha
ng
e 
in
 c
el
ls
1
n.s.n.s. **
FD E
G
ChowA WSD B Chow WSD C Chow WSD
CD
11
c
Co
nv
	-
w
at
er
Co
nv
	-
AB
X
AS
F
Ge
rm
-fr
ee
CD11b CD11bCD64
CD
10
3
Ly
6-
G
Figure	4.	Microbiota	ablation	reduces	dendritic	cell	alterations	and	neutrophil	cell	
infiltration	in	the	colon.	
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Figure 3.6-5. Genetic depletion of TLR-signaling adaptor MyD88 phenocopies 
microbiota ablation in response to WSD. 
Conventionally-raised 3-5-week old, male C57BL/6J, wild type and MyD88KO mice were 
purchased from The Jackson Laboratory. Animals were placed on a high-fat diet (60% kcal from 
fat) for 8 weeks or continued on a standard grain-based chow as a control. At day 56, mice were 
euthanized for tissue collection and biometric measurements, data of WSD-treated mice 
represented here is relative to the chow-fed mice of their corresponding groups: (A) final body 
weight, (B) visceral adipose tissue weight, (C) 15-hour fasting blood glucose, (D) ALT, AST, total 
cholesterol, (E) colon weight/length ratio, and (F) spleen weight. Visceral adipose tissue from the 
epididymitis of mice was analyzed utilizing flow cytometry and qRT-PCR to quantify: (G) 
macrophages, (H-I) M1 macrophages, (J-K) M2 macrophages, (L) M1:M2 ratio, (M) 
inflammatory cytokines, and (N) eosinophils. Colon tissue were used to quantify: (O) dendritic 
cells, (P) CD103- dendritic cells, (Q) CD103+ dendritic cells, and (R) neutrophils. Data are the 
means +/- S.E.M. Statistical significance was determined using t-test (*p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001, n.s. indicates non-significant). 
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Figure	5.	Genetic	depletion	of	TLR-signaling	adaptor	MyD88	phenocopies	microbiota	
ablation	in	response	to	WSD.	
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3.7 Supplemental Figures and Legends 
 
Figure 3.7-1. Gating scheme for myeloid cells in adipose, small intestine, colon tissue, 
spleen, and Peyer’s Patches. 
All cells were gated for appropriate SSC-A/FSC-A and singlets. Data was collected until 
100,000 events was reached in the Live/CD45+ gate. (A) Gating scheme of macrophages from 
visceral adipose and intestinal tissue. Live CD45+MHCII+ cells were identified as macrophages 
if they were F4/80+ (or CD11b+) and CD64+. Of visceral adipose tissue macrophages, M1 
macrophages were identified as CD301-, M2 macrophages were identified as CD301+. (B) Gating 
scheme of dendritic cells from visceral adipose and intestinal tissue. Live CD45+MHCII+ cells 
were identified as dendritic cells if they were CD11c+ but CD64-. Dendritic cells subsets were 
identified as either CD11b+CD103- (Q3) or CD11b-CD103+ (Q1) in the adipose or CD103+/- in 
the small intestine and colon. (C) Gating scheme of eosinophils and neutrophils from visceral 
Supplemental	Figure	1.	Gating	scheme	for	myeloid	cells	in	adipose,	small	intestine,	colon	
tissue,	spleen,	and	Peyer’s	Patches.
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adipose and intestinal tissue. Live CD45+MHCII- cells were identified as eosinophils if they were 
Siglec-F+Ly6-G- or neutrophils if they were Siglec-F-Ly6-G+, these populations are also both 
CD11b+. (D) Gating scheme of myeloid cells from splenic tissue. Live CD45+MHCII+ cells were 
gated to exclude B cells (CD19+) and T cells (CD3+). Of this CD45+MHCII+CD19-CD3- 
population, CD11chigh cells were classified as dendritic cells, which were then classified as either 
CD8+/-, while CD11b+CD11c- cells were categorized as either eosinophils (Ly6-CloGr-1-), 
neutrophils (Gr-1+), or inflammatory monocytes (Ly6-ChighGr-1-). (E) Gating scheme of dendritic 
cells from Peyer’s Patches. Dendritic cells were identified as live CD11c+ and subdivided as either 
preDCs or mature DCs based on MHCII expression. Mature MHCII+ DCs were categorized as 
either myeloid DCs (CD8a-CD11b+) or lymphoid DCs (CD8a+CD11b-). 
 
 
Figure 3.7-2. An obesogenic diet alters myeloid cell populations in the small intestine, 
and to a lesser extent in the spleen and Peyer’s Patches. 
Following 8-weeks on a chow or WSD, mice were euthanized and (A) colon tissue was 
analyzed for macrophages. Small intestinal tissue was analyzed for: (B) dendritic cells, (C) 
CD103+/- dendritic cells, (D) eosinophils, neutrophils, and (E) macrophages. Splenic tissue was 
analyzed for (F) eosinophils, neutrophils, inflammatory monocytes, and (G) CD8+/- cDCs. Peyer’s 
Patches were analyzed for (H-I) total dendritic cells and dendritic cell subsets. Data are the means 
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Supplemental	Figure	2.	An	obesogenic	di t	alters	myeloid	cell	populations	in	the	small	
intestine,	a d	to	a	lesser	extent	in	the	spleen	and	Peyer’s	Patches.	
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+/- S.E.M. Statistical significance was determined using t-test (brackets indicates significance, 
p<0.05). 
 
 
Figure 3.7-3. Absolute values of biometric measurements and tissue/macromolecule 
quantifications. 
Comparison of conventional mice to antibiotic-treat, ASF, and germ-free mice: (A) final 
body weight, (B) visceral adipose tissue weight, (C) subcutaneous adipose tissue weight, (D) 
brown adipose tissue weight, (E) fasting blood glucose, (F) ALT, (G) AST, (H) total serum 
cholesterol, (I) liver weight, (J) colon weight/length ratio, and (K) spleen weight. Comparison of 
Wild Type mice to MyD88 KO mice: (L) body weight, (M) visceral adipose tissue weight, (N) 15-
hour fasting blood glucose, (O) colon weight/length ratio, (P) ALT, AST, total cholesterol, (Q) 
spleen weight. Data are the means +/- S.E.M. Statistical significance was determined using t-test 
(*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, n.s. indicates non-significant). 
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Supplemental	Figure	3.	Absolute	values	of	biometric	measurements	and	
tissue/macromolecule	quantifications.		
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Figure 3.7-4. Microbiota ablation modestly protects against eosinophil loss during WSD-
feeding. 
Visceral adipose tissue from the epididymitis of mice was analyzed utilizing flow cytometry 
to quantify (A) eosinophils. (B) Eosinophils of WSD-treated mice represented as the number per 
gram of adipose tissue is relative to chow-fed mice. Data are the means +/- S.E.M. Statistical 
significance was determined using t-test (*p≤0.05, **p≤0.01, n.s. indicates non-significant). 
 
Supplemental	Figure	4.	Microbiota	ablation	modestly	protects	against	eosinophil	loss	during	
WSD-feeding.	
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Figure 3.7-5. Transplant of microbiota from obese mice mildly recapitulates features of 
obesity and myeloid cell alterations. 
4-week old, male C57BL/6 germ-free mice were purchased from Taconic Biosciences and 
were administered feces from either chow- or WSD-fed mice by oral gavage. These animals were 
subsequently maintained in a sterile environment for 4 weeks before terminal tissue collection and 
biometric quantification, data represented here: (A) final body weight, (B) visceral adipose tissue 
weight, (C) subcutaneous adipose tissue weight, (D) brown adipose tissue weight, (E) 15-hour 
fasting blood glucose, (F) ALT, AST, total serum cholesterol, (G) liver weight, (H) colon 
weight/length ratio, and (I) spleen weight. Visceral adipose tissue was analyzed using flow 
cytometry to quantify: (J) macrophages, (K-L) M1 macrophages, (M-N) M2 macrophages, (O) 
M1:M2 ratio, and (P) eosinophils. Visceral adipose tissue collected at euthanasia was also 
analyzed for (Q) cytokines via qRT-PCR. Colon tissue was analyzed using flow cytometry to 
quantify: (R) dendritic cells, (S) CD103- dendritic cells, (T) CD103+ dendritic cells, and (U) 
neutrophils. Data are the means +/- S.E.M. Statistical significance was determined using t-test 
(brackets indicates significance, p<0.05). 
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Supplemental	Figure	5.	Transplant	of	microbiota	from	obese	mice	mildly	recapitulates	
features	of	ob sity	and	myeloid	cell	ab rrations.	
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3.8 Supplemental Tables 
Table 3.8-1. Staining Cocktail for Adipose Tissue and Colonic Tissue Macrophages. 
 
Table 3.8-2. Splenic Tissue Staining Cocktail. 
 
Table 3.8-3. Peyer's Patch Staining Cocktail. 
 
Table 3.8-4. Staining Cocktail for Adipose Tissue and Colonic Tissue Dendritic Cells. 
  
Supplemental	Table	1
Marker Fluorophore Dilution Supplier
CD11c PacBlue 1:100 eBioscience
CD301 APC 1:50 Biolegend
CD45 PerCP 1:100 Biolegend
CD64 PE/Dazzle 1:100 Biolegend
F4/80	(or	CD11b) PE 1:100 Biolegend
MHCII AF700 1:100 eBioscience
Supplemental	Table	2
Marker Fluorophore Dilution Supplier
CD11b Pe/Cy5 1:100 Biolegend
CD11c Pe/Cy7 1:300 Biolegend
CD19 APC 1:100 eBioscience
CD3 PE 1:100 Biolegend
CD45 PerCP 1:100 Biolegend
CD8 eFluor	450 1:100 eBioscience
Gr-1 FITC 1:100 Biolegend
Ly6-C BV605 1:100 Biolegend
Supplemental	Table	3
Marker Fluorophore Dilution Supplier
CD11b Pe/Cy5 1:100 Biolegend
CD11c APC 1:100 Biolegend
CD8a eFluor	450 1:100 eBioscience
MHCII AF700 1:100 eBioscience
Supplemental	Table	4
Marker Fluorophore Dilution Supplier
CD103 APC 1:50 Biolegend
CD11b PE 1:100 Biolegend
CD11c PacBlue 1:100 Biolegend
CD45 PerCP 1:100 Biolegend
CD64 PE/Dazzle 1:100 Biolegend
MHCII AF700 1:100 eBioscience
Supplemental	Table	5
Marker Fluorophore Dilution Supplier
CD11b PE 1:100 Biolegend
Ly6-G FITC 1:100 Biolegend
MHCII AF700 1:100 eBioscience
Siglec-F BV421 1:100 BD	BioScience
CD45 PerCP 1:100 Biolegend
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Eosinophils	and	Neutrophils
Splenic	Tissue	Staining	Cocktail
Peyer's	Patch	Staining	Cocktail
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Macrophages
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Dendritic	Cells
Supplemental	Table	1
Marker Fluorophore Dilution Supplier
CD11c PacBlue 1:100 eBioscience
CD301 APC 1:50 Biolegend
CD45 PerCP : i leg d
CD64 PE/Dazzle 1:100 i l
F4/80	(or	CD11b) PE : i l
MHCII AF700 : e i sci ce
Supplemental	Table	2
Marker Fluorophore Dilution Supplier
CD11b Pe/Cy5 1:100 Biolegend
CD11c Pe/Cy7 1:300 Biolegend
CD19 APC : e i sci ce
CD3 PE :1 i l
45 Per P : i leg d
8 eFluor	450 : e i sci ce
Gr-1 FITC : i l
Ly6-C BV605 i leg d
Supplemental	Table	3
Marker Fluorophore Dilution Supplier
CD11b Pe/Cy5 1:100 Biolegend
CD11c APC 1:100 Biolegend
CD8a eFluor	450 e i sci ce
MHCII AF700 e i sci ce
Supplemental	Table	4
Marker Fluoro hore Dilution Supplier
CD103 APC 1:50 Biolegend
CD11b PE 1:100 Biolegend
1c PacBlue 1:100
CD45 PerCP
CD64 PE/Dazzle
MHCII AF700 e i sci ce
Supplemental	Table	5
Marker Fluoro hore Dilution Supplier
CD11b PE 1:100 Biolegend
Ly6-G FITC 1:100 Biolegend
MHCII AF700 e i sci ce
Siglec-F BV421 BD	BioScience
CD45 PerCP i leg d
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Eosinophils	and	Neutrophils
Splenic	Tissue	Staining	Cocktail
Peyer's	Patch	Staining	Cocktail
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Macrophages
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Dendritic	Cells
Supplemental	Table	1
Marker Fluorophore Dilution Supplier
CD11c PacBlue 1:100 eBioscience
CD301 APC 1:50 Biolegend
CD45 PerCP 1:100 Biolegend
CD64 PE/Dazzle 1:100 Biolegend
F4/80	(or	CD11b) PE 1:100 Biolegend
MHCII AF700 1:100 eBioscience
Supplemental	Table	2
Marker Fluorophore Dilution Supplier
CD11b Pe/Cy5 1:100 Biolegend
CD11c Pe/Cy7 1:300 Biolegend
CD19 APC 1:100 eBioscience
CD3 PE 1:100 Biolegend
CD45 PerCP 1:100 Biolegend
CD8 eFluor	450 1:100 eBioscience
Gr-1 FITC 1:100 Biolegend
Ly6-C BV605 1:100 Biolegend
Supplemental	Table	3
Marker Fluorophore Dilution Supplier
CD11b Pe/Cy5 1:100 Biolegend
CD11c APC 1:100 Biolegend
CD8a eFluor	450 1:100 eBioscience
MHCII AF700 1:100 eBioscience
Supplemental	Table	4
Marker Fluorophore Dilution Supplier
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CD11b PE 1:100 Biolegend
CD11c PacBlue 1:100 Biolegend
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CD64 PE/Dazzle 1:100 Biolegend
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CD45 PerCP 1:100 Biolegend
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Eosinophils	and	Neutrophils
Splenic	Tissue	Staining	Cocktail
Peyer's	Patch	Staining	Cocktail
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Macrophages
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Dendritic	Cells
Supplemental	Table	1
Marker Fluorophore Dilution Supplier
CD11c PacBlue 1:100 eBioscience
CD301 APC 1:50 Biolegend
CD45 PerCP : i leg d
CD64 PE/Dazzle 1:100 i l
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Supplemental	Table	2
Marker Fluorophore Dilution Supplier
CD11b Pe/Cy5 1:100 Biolegend
CD11c Pe/Cy7 1:300 Biolegend
CD19 APC 1:100 eBioscience
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Supplemental	Table	3
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Supplemental	Table	4
Marker Fluorophore Dilution Supplier
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CD11b PE 1:100 Biolegend
CD11c PacBlue 1:100 Biolegend
CD45 PerCP 1:100 Biolegend
CD64 PE/Dazzle 1:100 Biolegend
MHCII AF700 1:100 eBioscience
Supplemental	Table	5
Marker Fluorophore Dilution Supplier
CD11b PE 1:100 Biolegend
Ly6-G FITC 1:100 Biolegend
MHCII AF700 1:100 eBioscience
Siglec-F BV421 1:100 BD	BioScience
CD45 PerCP 1:100 Biolegend
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Eosinophils	and	Neutrophils
Splenic	Tissue	Staining	Cocktail
Peyer's	Patch	Staining	Cocktail
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Macrophages
Staining	Cocktail	for	Adipose	Tissue	and	Colonic	Tissue	
Dendritic	Cells
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Table 3.8-5. Staining Cocktail for Adipose Tissue and Colonic Tissue Eosinophils and 
Neutrophils. 
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4 INTERACTIONS BETWEEN THE ADAPTIVE IMMUNE SYSTEM AND THE 
INTESTINAL MICROBIOTA 
4.1 Abstract 
The intestinal microbiota is a large and diverse microbial community that inhabits the 
intestine, containing about 100 trillion bacteria of 500-2000 distinct species that, collectively, 
provide benefits to the host. The human gut microbiota composition is determined by a myriad of 
factors, among them genetic and environmental, including diet and medication. The microbiota 
contributes to nutrient absorption and maturation of the immune system. As reciprocity, the host 
immune system plays a central role in shaping the composition and localization of the intestinal 
microbiota. Secretory immunoglobulins A (sIgAs), component of the adaptive immune system, 
are important player in the protection of epithelium, and are known to have an important impact 
on the regulation of microbiota composition. A recent study published in Immunity by Fransen and 
colleagues aimed to mechanistically decipher the interrelationship between sIgA and microbiota 
diversity/composition. This commentary will discuss these important new findings, as well as how 
future therapies can ultimately benefit from such discovery. 
 
4.2 Introduction 
The gut host defense system comprises an array of mechanisms to keep the microbiota in 
check, maintaining an orderly, beneficial relationship with the intestinal microbiota 131. These 
mechanisms include the presence of multi-layered mucus structures, secretion of anti-microbial 
peptides and the secretion of sIgA. Additionally, the mucosal immune system has several means 
to sample and evaluate potential danger of microbiota-derived antigens, allowing production of 
specific antibodies to bacterial antigens that might compromise the host. Adaptive immunity in 
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general, and sIgA in particular, is known to play a key role in microbiota composition. Here, we 
will discuss recent findings132 describing how IgAs population has an impact on microbiota 
diversity, and how they may provide therapeutic insights into diseases associated with dysbiosis. 
 
4.3 Immunoglobulin A-mediated modulation of the intestinal microbiota 
A key intestinal strategy to generate immune protection in a non-inflammatory manner is 
the production of IgA133-135, which is schematically illustrated in Figure 4.7-1, as well as the 
interplay between IgA and the microbiota in the intestine. One of the main role played by IgA is 
the promotion of immune exclusion by entrapping dietary antigens and microorganisms in the 
mucus, or down-regulating the expression of pro-inflammatory bacterial epitopes on commensal 
bacteria, such as flagellin136. The IgA population in the gut is central for the selection and the 
maintenance of the intestinal microbiota137, 138.  
The main observation showing the importance of immunoglobulin in microbiota 
composition regulation was made with animals lacking such Ig production. The microbiota 
analysis of RAG1-/- mice (which have no adaptive immune system owing to the lack of V(D)J 
recombination-activating protein 1 (RAG1)) revealed profound alterations in their microbiota 
composition139. Moreover, it was observed that the restoration of normal IgA levels in AID 
(activation-induced cytidine deaminase) deficient mice, which normally lack IgAs, is sufficient to 
restore a normal microbiota composition137, 140, 141. Another important observation showing that 
intestinal IgA help to shape the intestinal microbiota is the recent finding that cessation of breast-
feeding to either formula or food drives the maturation of the infant gut microbiome, indicating 
that the important amount of IgA secreted in mother's milk seems to play a central role in the 
regulation of microbiota composition142. Mounting evidence clearly reveals that bacterial species 
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colonizing the gut differ in their ability to stimulate the post-natal maturation of the gut system, 
with a good example being segmented filamentous bacteria (SFB) which are potent stimuli of IgA 
responses and strong inducers of Peyer’s patches development143, 144. 
 
4.4 Polyreactive IgA diversity controls microbiota composition and diversity 
Fransen and collaborators recently demonstrated that the abundance and repertoire 
diversity of innate IgAs play a central role in regulating the diversity of the intestinal microbiota132. 
The authors observed that C57BL/6 and BALB/c mice differ drastically in their IgA abundance 
and repertoire richness, which associate with profound differences in their microbiota composition. 
While BALB/c mice have a high abundance and diversity of IgAs, C57BL/6 mice harbor a poor 
IgA repertoire correlating with decreased microbiota diversity. Even under germfree conditions 
(germfree animals are devoid of any microorganisms), C57BL/6 and BALB/c mice differ in 
polyreactive IgA, revealing a genetic component of IgA production. Importantly, those 
polyreactive IgA were found by the authors to determinate the capacity of the strain of mice to 
diversify the microbiota. Delving deeper into the mechanisms of such interrelationship between 
polyreactive IgA and microbiota diversity, the authors demonstrated that polyreactive IgAs are 
required to trigger IgA response toward members of the intestinal microbiota, through a coating 
that favor bacterial penetration into Peyer’s patches132. Those findings further demonstrate that 
microbiota diversity is both genetically and environmentally driven, mechanistically supporting 
earlier observations145.  
However, it is important to note that low IgA diversity is not the exclusive discrepancy 
found between these 2 mice strains. Among other differences, C57BL/6 mice have a normal Th1 
response while BALB/c mice are deficient in Th1 signaling, which could also have an important 
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impact on the phenotypes described in this study. One important point that still needs to be 
addressed is whether the decreased microbiota diversity observed in C57BL/6 mice, as a result of 
low IgA diversity, is associated with an increased pro-inflammatory potential/harmfulness. The 
investigations of whether the altered microbiota associated with low intestinal IgA predispose mice 
of subsequent challenges still need to be conducted. 
 
4.5 Immunoglobulin-based therapy for microbiota composition alteration and restoration 
It is important to note that, in their study, co-housing or fecal transplantation had little 
effect on both IgA production and microbiota composition, highlighting the stability of the 
intestinal microbiota in an individual, with a central role played by IgA repertoire132. The defined 
repertoire of IgAs controls the colonization and composition of the microbiota and will lead to the 
restoration of the original microbiota following alteration. Consequently, such findings suggest 
that modulation of IgA repertoire could lead to a more drastic and stable alteration in the intestinal 
microbiota compared to, for example, fecal transplantation. Moreover, it has been observed that 
mice bred in different facilities harbor a distinct microbiota that further determines the levels of 
secretory IgA. This study demonstrates that transfer of a microbiota from an IgA-low mice, by co-
housing or fecal transplantation, can lower fecal IgA levels in IgA-high mice146. This study also 
shows that IgA-low mice are more susceptible to challenges such as Dextran Sulfate Sodium 
(DSS)-induced colitis, and that such susceptibility can be transferred to IgA-high mice by fecal 
transplantation and are driven by fecal IgA differences via a mechanism involving the ability of 
bacteria from IgA-low mice to degrade sIgA146. Altogether, those findings highlight the close 
relationship occurring between sIgA repertoire and the microbiota, with a key role played in the 
maintenance of intestinal homeostasis. 
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A common feature of colitis-associated microbiota are increased levels of bioactive 
flagellin and lipopolysaccharide (LPS), which can activate Toll-like receptor 5 (TLR5), NOD-like 
Receptor 4 (NLRC4) inflammasome, and TLR481, 147, 148. Approaches to manipulate the microbiota 
to make it inherently less pro-inflammatory (i.e. reduce levels of innate immune activators) may 
ultimately provide a novel approach to prevent and/or treat Inflammatory Bowel Disease (IBD). 
Published observations demonstrating that the level of microbiota flagellin expression inversely 
correlates with levels of fecal anti-flagellin antibodies suggests that the adaptive immune system 
possess the ability to alter the microbiota to make it less pro-inflammatory (Figure 4.7-1)57, 77. 
Indeed, in a study published in Cell Host and Microbes in 2013, it was demonstrated that TLR5-/- 
mice harbor a reduced level of flagellin specific IgA57. Importantly, the intestinal microbiota of 
those TLR5-/- animals was found to express significantly higher amounts of bioactive flagellin, 
supporting an impact of intestinal IgA in suppressing levels of flagellin, likely by putting 
flagellated bacteria at a competitive disadvantage within a complex microbial community. 
In addition, recent findings made by flow-cytometric sorting suggest that IgA may mark 
commensal and pathobionts according to the extent of their individual coating149. The study from 
Palm and colleagues show that IgA coating selectively marks known disease-driving members of 
the mouse and human intestinal microbiota that can impact disease susceptibility and/or 
severity149. Transfer of fecal IgA-coated from cohorts of Kwashiorkor undernourished children 
into germ free mice triggers a diet-dependent enteropathy with intestinal inflammation and 
dysfunction, but could be prevented by administering two IgA-targeted bacterial species 
(Clostridium scindens, Akkermansia muciniphila) from a healthy microbiota150. A targeted 
elimination or replacement of disease-driving members of the intestinal microbiota could be a first 
step in the development of personalized, microbiota reshaping therapies 
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4.6 Conclusions 
Based on this exciting work by Rescigno and colleagues, we can hypothesis that selected 
manipulation of the immune system has the potential to alter gut microbiota composition to make 
it inherently less pro-inflammatory (i.e. more diverse and with a reduced level of innate immune 
activators), reducing susceptibility to and/or severity of intestinal inflammation development. IgA 
may be used as a target to shape the intestinal bacterial community in order to maintain a beneficial 
relationship between the host and the microbiota. 
4.7 Figure and Legends 
 
Figure 4.7-1. Interplay between IgA and the microbiota in the intestine. 
Schematic representation of IgA generation in the intestine, and how IgA population and 
intestinal microbiota regulate each other. Symbol 1: intestinal antigen sampling, mainly through 
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M-cells process, is the first step in IgA plasma cells generation and IgA synthesis. IgA population 
and diversity will depend on antigenic peptides presented to the immune system by antigen-
presenting cell. Symbol 2: after interaction with its receptor (pIgR), IgA dimers are translocated 
to the lumen where they will provide mucosal immune protection. In addition, such secreted IgA 
can subsequently regulate microbiota composition, diversity, and gene expression. SED: sub-
epithelial dome; DC: dendritic cell.  
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5 FLAGELLIN-ELICITED ADAPTIVE IMMUNITY SUPPRESSES FLAGELLATED 
MICROBIOTA AND VACCINATES AGAINST CHRONIC INFLAMMATORY 
DISEASES. 
5.1 Abstract 
Gut microbiota composition is increasingly appreciated to be an important determinant of 
chronic inflammatory diseases, including Inflammatory Bowel Disease (IBD) and metabolic 
syndrome. One feature of inflammation-associated gut microbiotas is enrichment of flagellin, 
which can both activate host pro-inflammatory gene expression and facilitate microbiota 
encroachment into the mucosa. Mucosal adaptive immunity, in particular flagellin-specific IgA, 
serves to suppress flagellin levels thus protecting against chronic gut inflammation. Hence, we 
hypothesized that elicitation of mucosal anti-flagellin antibodies via direct administration of 
purified flagellin might serve as a general vaccine against subsequent development of chronic gut 
inflammation. Accordingly, we observed that, in mice, repeated injection of flagellin elicited 
marked increases in fecal anti-flagellin IgA, altered microbiota composition, reduced fecal 
flagellin concentration, and prevented microbiota encroachment. Flagellin’s impact on the 
microbiota was B-lymphocyte dependent, protected against IL-10 deficiency-induced colitis and 
ameliorated diet-induced obesity. Moreover, we found that, in humans, relative to normal weight 
subjects, obese subjects exhibited increased levels of fecal flagellin and reduced levels of fecal 
flagellin-specific IgA. Thus, administration of flagellin, and perhaps other pathobiont antigens, 
may be a means of vaccinating against chronic inflammatory diseases. 
 
5.2 Introduction 
An array of chronic inflammatory diseases are associated with dysbiosis in the intestinal 
microbiota and a breakdown in the normally mutually beneficial host-microbiota relationship. 
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Such diseases include Inflammatory Bowel Diseases (IBD) and diseases characterized by low-
grade inflammation, such as metabolic syndrome. Perturbations in the microbiota do not merely 
mark disease. Rather, that microbiota transplantation from IBD patients or colitic animals to 
germfree recipient mice results in intestinal inflammation argues altered microbiota plays a key 
role in driving inflammatory disease81, 82, 99, 151, 152. While the specific alterations in microbiota 
composition associated with inflammation vary across study cohorts, common features of 
dysbiosis frequently include reduced species diversity and increase relative abundance of 
Proteobacteria98, 153. Moreover, we previously reported that, whether induced by transient presence 
of a pathobiont, an innate immune deficiency, or the consumption of dietary emulsifiers 
(commonly used food additive with detergent-like properties), one common feature of 
inflammation-associated microbiotas is increased levels of flagellin, which can occur due to 
changes in species composition and/or microbial gene expression57, 81, 82, 147, 148. The link between 
elevated microbiota flagellin levels and intestinal inflammation is thought to involve flagellin’s 
ability to activate pro-inflammatory gene expression via TLR5 and the NLRC4 inflammasome. 
Additionally, as the structural component of flagella, elevated levels of flagellin might reflect 
enriched levels of motile bacteria that have high ability to penetrate the mucus layer that serves to 
protect the host against microbial onslaught.  
In accord with the notion that a microbiota expressing high levels of flagellin pose danger 
to the host, flagellin is also a dominant target of adaptive mucosal immunity, particularly in 
Crohn’s disease154. Yet, like many disease-associated immune responses, adaptive immunity to 
flagellin likely plays an important role in keeping microbes in check. Specifically, the coating of 
gut bacteria by flagellin-specific IgA, which normally occurs in homeostasis, suppresses levels of 
flagellated bacteria and guards against microbiota encroachment, which is thought to play a role 
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in promoting both IBD and metabolic syndrome57, 129, 155, 156. Hence, we hypothesize that boosting 
levels of mucosal flagellin-specific IgA might help keep flagellated bacteria in check and, 
consequently protect against development of chronic gut inflammation. Herein, we describe that 
repeated systemic administration of purified flagellin elicits a robust anti-flagellin fecal IgA 
response that serves to reshape microbiota composition, reduce flagellin expression, and protect 
against experimental colitis and metabolic syndrome. 
 
5.3 Experimental Procedures 
5.3.1 Mice and flagellin immunization 
Flagellin was purified from Salmonella Typhimurium (SL3201, fljB−), as we previously 
reported that antibodies directed against Salmonella Typhimurium crossreact with flagellin from 
numerous other bacteria57. Purity was verified as previously described157, 158. C57BL/6 mice (WT, 
TLR5/NLRC4 DKO159, MuMT160, IL10KO161) were maintained at Georgia State University, 
Atlanta, Georgia, USA under institutionally approved protocol under approved protocols (IACUC 
# A14033). Animals were immunized with 10 µg of flagellin through intraperitoneal injections 
weekly for a total of 10 injections, with control mice being treated with vehicle. For experiments 
utilizing anti-IL10R antibody, 1 mg of anti-IL10R (Bio X Cell) antibody was administered through 
intraperitoneal injections following flagellin immunization weekly for 4 weeks. For DIO model, 
mice were fed with a 60% kcal from fat (Research Diet, D12492) for 4 weeks. Mice were then 
euthanized, and colon length, colon weight, spleen weight and adipose weight were measure. 
Serum, feces, and organs were collected for downstream analysis. 
 
84 
5.3.2 Fecal sample preparation for immunoglobulin quantification. 
Fecal sample preparation of ELISA has been previously described76. 100 mg of fecal 
pellets were homogenized in 3 mL of collection media consisting of 0.05 mg soybean trypsin 
inhibitor per ml of a 3:1 mixture of 1X PBS and 0.1 M EDTA, pH 7.4. Following centrifugation 
at 1800 rpm for 10 minutes, the supernatant was centrifuged again at 14,000 rpm for 15 minutes 
at 4°C, and final supernatant was collected and stored with 20% glycerol and 2 mM 
phenylmethylsulfonyl fluoride (Sigma, P-7626) at -20°C until analysis. 
 
5.3.3 Fecal and Serum anti-flagellin IgA/IgG 
Quantification of anti-flagellin- specific IgA and IgG has been previously described77-79. 
Briefly, 96-well microtiter plates (Costar, Corning, New York) were coated with 100 ng/well of 
laboratory-made flagellin in 9.6 pH bicarbonate buffer overnight at 4° C. Serum samples from 
mice were then applied either pure or at a 1:100 dilution for 1 hour at 37° C. After incubation and 
washing, the wells were incubated with either horseradish peroxidase-linked anti-mouse IgG (GE 
Healthcare Life Sciences, Pittsburgh, Pennsylvania) or horseradish peroxidase-linked anti-IgA 
(Southern Biotech, Birmingham, Alabama). Quantification of immunoglobulin was then 
developed by the addition of 3,3’,5,5’-Tetramethylbenzidine and the optical density was calculated 
by the difference between readings at 450nm and 540nm.  
 
5.3.4 Fecal Lcn-2 quantification 
As previously described80, frozen fecal samples were reconstituted in PBS containing 0.1% 
Tween 20 at 100 mg/ml and vortexed for 20 min. The homogenate was then centrifuged at 12,000 
rpm for 10 min at 4°C. Clear supernatants were collected and stored at −20°C until analysis. Lcn-
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2 levels were measured in the supernatants using Duoset murine Lcn-2 ELISA kit (R&D Systems, 
Minneapolis, MN). 
 
5.3.5 Myeloperoxidase quantification 
Tissue samples were homogenized in 100 mg/mL of 0.5% hexadecyltrimethylammonium 
bromide (Sigma, St. Louis, MO) in 50 mM PBS, pH 6.0, as previously described80. Following 3 
cycles of freeze-thaw at -80°C and 37°C, samples were sonicated and centrifuged at 14,000 rpm 
for 15 min at 4°C. Supernatants were stored at −20°C until analysis. MPO was assayed in the 
supernatant by adding 1 mg/mL of dianisidine dihydrochloride (Sigma, St. Louis, MO) and 
5×10−4% H2O2 and the change in optical density measured at 450 nm. 
 
5.3.6 Serum CXCL1 and IL-6 quantification 
Serum chemokine (C-X-C motif) ligand 1 (CXCL1) and Interleukin-6 (IL-6) 
concentrations were determined using Duoset cytokine ELISA kits (R&D Systems, Minneapolis, 
MN) according to manufacturer’s instructions80. 
 
5.3.7 Fecal flagellin and lipopolysaccharide load quantification 
We quantified flagellin and lipopolysaccharide (LPS) as previously described using human 
embryonic kidney (HEK)-Blue-mTLR5 and HEK-BluemTLR4 cells, respectively (Invivogen, San 
Diego, California, USA)81, 82. We resuspended fecal material in PBS to a final concentration of 
100 mg/mL and homogenized for 10 s using a Mini-Beadbeater-24 without the addition of beads 
to avoid bacteria disruption. We then centrifuged the samples at 8000 g for 2 min, serially diluted 
the resulting supernatant, and applied to mammalian cells. Purified E. coli flagellin and LPS 
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(Sigma, St Louis, Missouri, USA) were used for standard curve determination using HEK-Blue-
mTLR5 and HEK-Blue-mTLR4 cells, respectively. After 24 h of stimulation, we applied cell 
culture supernatant to QUANTI-Blue medium (Invivogen, San Diego, California, USA) and 
measured alkaline phosphatase activity at 620 nm after 30 min. 
 
5.3.8 Microbiota analysis by 16S rRNA gene sequencing using Illumina MiSeq technology 
16S rRNA gene amplification and sequencing were done using the Illumina MiSeq 
technology following the protocol of Earth Microbiome Project with their modifications to the 
MOBIO PowerSoil DNA Isolation Kit procedure for extracting DNA 
(www.earthmicrobiome.org/emp-standard-protocols). Bulk DNA were extracted from frozen 
extruded feces using a PowerSoil-htp kit from MoBio Laboratories (Carlsbad, California, USA) 
with mechanical disruption (bead-beating). The 16S rRNA genes, region V4, were PCR amplified 
from each sample using a composite forward primer and a reverse primer containing a unique 12-
base barcode, designed using the Golay error-correcting scheme, which was used to tag PCR 
products from respective samples 38. We used the forward primer 515F 5’-
AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTGTGCCAGCMGCCGCGGT 
AA-3’: the italicized sequence is the 5’ Illumina adapter B, the bold sequence is the primer pad, 
the italicized and bold sequence is the primer linker and the underlined sequence is the conserved 
bacterial primer 515F. The reverse primer 806R used was 5’-
CAAGCAGAAGACGGCATACGAGAT XXXXXXXXXXXX AGTCAGTCAG CCGGACTACH
VGGGTWTCTAAT-3’: the italicized sequence is the 3’ reverse complement sequence of Illumina 
adapter, the 12 X sequence is the golay barcode, the bold sequence is the primer pad, the italicized 
and bold sequence is the primer linker and the underlined sequence is the conserved bacterial 
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primer 806R. PCR reactions consisted of Hot Master PCR mix (Five Prime), 0.2 µM of each 
primer, 10-100 ng template, and reaction conditions were 3 min at 95°C, followed by 30 cycles of 
45 s at 95°C, 60s at 50°C and 90 s at 72°C on a Biorad thermocycler. Four independent PCRs were 
performed for each sample, combined, purified with Ampure magnetic purification beads 
(Agencourt), and products were visualized by gel electrophoresis. Products were then quantified 
(BIOTEK Fluorescence Spectrophotometer) using Quant-iT PicoGreen dsDNA assay. A master 
DNA pool was generated from the purified products in equimolar ratios. The pooled products were 
quantified using Quant-iT PicoGreen dsDNA assay and then sequenced using an Illumina MiSeq 
sequencer (paired-end reads, 2 × 250 bp) at Cornell University, Ithaca. 
 
5.3.9 Hematoxylin & eosin staining of colonic tissue and histopathologic analysis 
Following euthanasia, colons (proximal colon, 2nd cm from the cecum) were placed in methanol-
Carnoy’s fixative solution (60% methanol, 30% chloroform, 10% glacial acetic acid) for a 
minimum of 3 h at room temperature. Tissues were then washed in methanol 2 x 30 min, ethanol 
2 x 15 min, ethanol/xylene (1:1) 15 min, and xylene 2 x 15 min, followed by embedding in paraffin 
with a vertical orientation. Tissues were sectioned at 5-m m thickness and stained with hematoxylin 
& eosin (H&E) using standard protocols. H&E stained slides were assigned four scores based on 
the degree of epithelial damage and inflammatory infiltrate in the mucosa, submucosa, and 
muscularis/serosa, as previously described 162. A slight modification was made to this scoring 
system, as we previously reported80: each of the four scores was multiplied by 1 if the change was 
focal, 2 if it was patchy and 3 if it was diffuse. The 4 individual scores per colon were added, 
resulting in a total scoring range of 0–36 per mouse. Representative images were selected. 
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5.3.10 Immunostaining of mucins and localization of bacteria by FISH 
Mucus immunostaining was paired with fluorescent in situ hybridization (FISH), as 
previously described163, in order to analyze bacteria localization at the surface of the intestinal 
mucosa81, 148. Briefly, colonic tissues (proximal colon, 2nd cm from the cecum) were placed in 
methanol-Carnoy’s fixative solution (60% methanol, 30% chloroform, 10% glacial acetic acid) for 
a minimum of 3 h at room temperature. Tissues were then washed in methanol 2 x 30 min, ethanol 
2 x 15 min, ethanol/xylene (1:1) 15 min, and xylene 2 x 15 min, followed by embedding in Paraffin 
with a vertical orientation. Five µm sections were performed and dewax by preheating at 60°C for 
10 min, followed by xylene 60°C for 10 min, xylene for 10 min and 99.5% ethanol for 10 minutes. 
Hybridization step was performed at 50°C overnight with EUB338 probe (5’-
GCTGCCTCCCGTAGGAGT-3’, with a 5' labeling using Alexa 647) diluted to a final 
concentration of 10 mg/mL in hybridization buffer (20 mM Tris–HCl, pH 7.4, 0.9 M NaCl, 0.1% 
SDS, 20% formamide). After washing 10 min in wash buffer (20 mM Tris–HCl, pH 7.4, 0.9 M 
NaCl) and 3 x 10 min in PBS, PAP pen (Sigma-Aldrich) was used to mark around the section and 
block solution (5% fetal bovine serum in PBS) was added for 30 min at 4°C. Mucin-2 primary 
antibody (rabbit H-300, Santa Cruz Biotechnology, Dallas, TX, USA) was diluted 1:1500 in block 
solution and apply overnight at 4°C. After washing 3 x 10 min in PBS, block solution containing 
anti-rabbit Alexa 488 secondary antibody diluted 1:1500, Phalloidin-Tetramethylrhodamine B 
isothiocyanate (Sigma-Aldrich) at 1µg/mL and Hoechst 33258 (Sigma-Aldrich) at 10 µg/mL was 
applied to the section for 2h. After washing 3 x 10 min in PBS slides were mounted using Prolong 
anti-fade mounting media (Life Technologies, Carlsbad, CA, USA). Observations were performed 
with a Zeiss LSM 700 confocal microscope with software Zen 2011 version 7.1. This software 
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was used to determine the distance between bacteria and epithelial cell monolayer, as well as the 
mucus thickness. 
 
5.3.11 16S rRNA gene sequence analysis 
Forward and reverse Illumina reads were joined using the fastq-join method84, 85, sequences 
were demultiplexed, quality filtered using Quantitative Insights Into Microbial Ecology (QIIME, 
version 1.8.0) software package86. QIIME default parameters were used for quality filtering (reads 
truncated at first low-quality base and excluded if: (1) there were more than three consecutive low 
quality base calls (2), less than 75% of read length was consecutive high-quality base calls (3), at 
least one uncalled base was present (4), more than 1.5 errors were present in the bar code (5), any 
Phred qualities were below 20, or (6) the length was less than 75 bases). Sequences were clustered 
to operational taxonomic units (OTUs) using UCLUST algorithm87 with a 97% threshold of 
pairwise identity (without the creation of new clusters with sequences that do not match the 
reference sequences), and taxonomically classified using the Greengenes reference database 
13_888. A single representative sequence for each OTU was aligned and a phylogenetic tree was 
built using FastTree89. The phylogenetic tree was used for computing the unweighted UniFrac 
distances between samples90, 91, rarefaction were performed and used to compare abundances of 
OTUs across samples. Principal coordinates analysis (PCoA) plots were used to assess the 
variation between experimental group (beta diversity). Alpha diversity curves were determined for 
all samples using the determination of the number of observed species. LEfSE (LDA Effect Size) 
was used to investigate bacterial members that drive differences between groups92. Unprocessed 
sequencing data will be deposited in the European Nucleotide Archive. 
 
90 
5.3.12 Human subjects 
All work involving human subjects used a previously existing stool collection, described 
in145, which was generated under approval by Cornell University (Ithaca NY); IRB Protocol ID 
1108002388.  
 
5.3.13 Statistical analysis 
Significance was determined using unpaired two-tailed t-test or one-way ANOVA with 
Bonferroni multiple comparisons test (GraphPad Prism software, version 6.01). Differences were 
noted as significant *p≤0.05 **p≤0.01 ***p≤0.001 ****p≤0.0001 for t-test and #p≤0.05 ##p≤0.01 
###p≤0.001 ####p≤0.0001 for one-way ANOVA. For clustering analyzing on principal coordinate 
plots, categories were compared and statistical significance of clustering were determined via 
Permanova. 
 
5.4 Results 
5.4.1 Systemic flagellin administrations elicits systemic and mucosal antibodies to flagellin  
The central hypothesis this study sought to test was that a regime of administration purified 
bacterial flagellin that elicited mucosal anti-flagellin antibodies might suppress levels of 
flagellated microbes and, consequently serve as a vaccine against chronic intestinal inflammation. 
A range of routes of administration were considered and tested. Orally administered flagellin failed 
to elicit a detectable immune response, likely reflecting its degradation by digestive tract proteases 
and/or inability to cross the mucosal epithelial surface that lines the gastrointestinal tract (data not 
shown). Nasally administered flagellin, with or without cholera toxin, elicited detectable levels of 
fecal and serum flagellin-specific antibodies, but did so with high variability (data not shown). 
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Hence, as a means to test our hypothesis, we opted for repeated intraperitoneal injections of 
flagellin (10 weekly injections) that resulted in a systemic and mucosal (fecal) level of anti-
flagellin antibodies (Fig. 5.6-1A-E). In accord with our previous studies, such adaptive immune 
responses depended upon flagellin’s ability to activate innate immunity in that mice lacking both 
flagellin receptors, namely TLR5 and NLRC4, exhibited a near complete loss of flagellin-elicited 
antibodies164 (Fig. 5.6-1F-G). Such weekly injections of flagellin did not themselves result in 
indications of overt clinical illness nor evidence of chronic inflammation, as evidenced by weekly 
measure of inflammatory marker fecal Lcn-280 and post euthanasia gross and histopathologic 
assessment of the colon (Fig. 5.6-3H and 5.7-1B). Moreover, the high levels of anti-flagellin 
attained did not prevent injected flagellin from continuing to potently activate TLR5-mediated 
cytokine production (Fig. 5.6-1H-I). Thus, we reasoned that IP injections served as a reasonable 
experimental model that could be used to explore how a high mucosal antibody response to 
flagellin might impact subsequent development of inflammatory disease.  
 
5.4.2 Flagellin administration alters the intestinal microbiota reducing its pro-inflammatory 
potential. 
We next analyzed the impact of our flagellin immunization regimen on the intestinal 
microbiota. We interrogated fecal microbiota composition by 16S rRNA gene sequencing and 
analyzed the unweighted Unifrac distance, as previously described81, 90. We utilized 2 cages of 
control and flagellin-immunized mice thus aiding our ability to distinguish any differences in 
composition due to “cage-clustering” vs. treatment. As expected, such an approach found 
microbiota composition were not different based on treatment at day -14. However, flagellin 
immunization lead to a strong alteration of microbiota composition in that both flagellin-treated 
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cages of mice were markedly distinct from the PBS-treated mice at day 56 using principal 
coordinate analysis of the unweighted Unifrac distance (Fig. 5.6-2A-B). In accord with this notion, 
despite the two cages of PBS-treated animals exhibiting distinct microbiotas due to cage clustering, 
LEfSe analysis revealed that multiple OTUs are significantly increased or decreased in relative 
abundance in fecal microbiota derived from FliC-treated animals compared to PBS-treated animals 
(Fig. 5.6-2C and 5.7-1A). We next investigated the functional consequences on these alterations 
in microbiota composition in FliC-treated mice. Using our previously described cell-based assay 
allowing the quantification of fecal bioactive flagellin81, 147, we observed that flagellin 
immunization resulted in decreased fecal flagellin relative to PBS-treated age- and gender-matched 
control mice (Fig. 5.6-2D), suggesting a less motile microbiota with less potential to encroach 
upon host epithelial cells and initiate intestinal inflammation, as highlighted by a decreased 
myeloperoxidase activity following immunization (Fig. 5.6-2E). To examine this possibility, we 
next examined microbiota localization, by measuring the extent to which gut bacteria had 
penetrated the mucus layer lining the intestine. In PBS-treated animals, the average closest bacteria 
per high-powered field microbiota were localized at 11.1 +/- 1.11 µm from the epithelium, while 
in FliC-treated animals, such closest microbiota were located 16.44 µm +/- 2.27 µm from the 
epithelium (P<0.05) (Fig 5.6-2F-G).  
While one can envisage a range of potential mechanisms whereby flagellin administration 
might impact the microbiota, we hypothesized that the flagellin-induced change in microbiota 
composition, flagellin levels, and localization observed here are the result of mucosal anti-flagellin 
antibodies. To test this notion, we next examined the extent to which mice unable to produce 
antibodies due to their lack of mature B cells, namely µMT mice, would also exhibit an increased 
microbiota/epithelial cells distance following immunization. Importantly, in µMT mice, flagellin 
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immuniziation regimen no longer resulted in an increase in bacterial–epithelial distance (Fig. 5.6-
2F-G), thus arguing that a significant portion of flagellin’s impact upon the microbiota is mediated 
by anti-flagellin antibodies.  
 
5.4.3 Flagellin administrations protect against immune dysregulation-induced colitis. 
Flagellin is reported to be a dominant antigenic driver of Crohn’s disease154, while 
microbiota encroachment is a feature of IBD in general155, 165. Hence, we hypothesized that the 
above-described immunization regimen, which decreased levels of flagellin and increased 
bacterial-epithelial distance, might protect mice against colitis. To examine this possibility, we 
subjected flagellin-immunized and control (PBS-treated) mice to immune dysregulation-induced 
colitis, which was achieved by weekly injections of a-IL-10 receptor neutralizing antibody. In 
accord with previous work, such blockade of IL-10 signaling resulted in typical features of colitis, 
including loss of weight/adiposity, splenomegaly, colomegaly, colon shortening, elevated MPO, 
increase in pathohistological scoring, and elevations in serum IL-6 and CXCL-1 (Fig. 5.6-3). 
Importantly, all of these parameters were reduced in flagellin-immunized mice, indicating that 
flagellin immunization had potential to protect against colitis (Fig. 5.6-3A-J). To determine if such 
protection was indeed dependant on flagellin-elicited antibodies, the experiment was repeated 
using µMT mice. Such mice did show indices of colitis, such as colon shortening, which was not 
prevented by flagellin immunization, suggesting that flagellin-elicited antibodies contribute to 
colitis protection (Fig. 5.6-3K). Next, multivariate test analysis using all the above described 
measures (Fig. 5.6-3A-K) was used to measure the impact of flagellin immunization on intestinal 
inflammation. Bray-Curtis distance, presented Fig. 5.6-3L-N, demonstrate that flagellin 
immunization is having a significant impact on WT animals in protecting them against intestinal 
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inflammation, while the protective effects are very modest in µMT mice, as highlighted by a 
smaller Bray-Curtis distance between immunized and non-immunized animals compared with WT 
animals (Fig. 5.6-3N).  
Another experimental approach to achieving loss of IL-10 function, thus making mice 
prone to developing microbiota-dependent colitis, is the use of mice lacking the IL-10 gene. Hence, 
we next immunized IL10KO mice subjected to flagellin treatment weekly from 4-14 weeks of age, 
and thereafter, examined the extent to which such flagellin immunization impacted their 
development of colitis. In accord with previous observations that IL10KO mice make robust, 
somewhat exaggerated immune responses, we observed that our immunization regimen not only 
induced robust fecal anti-flagellin IgA, but IgG as well (Fig. 5.7-2A-B). While the control (PBS-
treated) IL10KO mice used here did not develop severe colitis, they did display short colons, and 
low but detectable level of colon MPO activity, both suggestive of chronic inflammation, which 
was attenuated by flagellin immunization (Fig. 5.7-2). These results support the notion that 
immunization with flagellin can protect against immune-dysregulation induced colitis. In contrast, 
flagellin immunization was not sufficient to protect mice against DSS colitis, which does not 
require immune dysregulation nor depend upon the presence of a microbiota166 (Fig. 5.7-3).  
 
5.4.4 Flagellin immunization protected against high-fat diet-induced obesity 
Recent work by ourselves and others have shown that microbiota encroachment is not only 
associated with IBD but also is a feature of metabolic syndrome in humans129. We suspected that 
one factor that might contribute to such microbiota encroachment is a relatively low amount of 
flagellin-specific mucosai IgA relative to the amount of flagellated bacteria present. To examine 
this possibility, we measured levels of flagellin and flagellin-specific IgA in a collection of fecal 
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samples previously isolated from subjects ranging in BMI from healthy to overweight and obese 
145. Consistent with our observations in mice, we found that anti-flagellin IgA levels were inversely 
proportional to flagellin in human feces (R2=0.39, Fig. 5.6-4A). We observed that levels of fecal 
flagellin were higher in overweight persons, relative to normal weight subjects, and further 
significantly increased in obese persons. In contrast, levels of flagellin-specific IgA were reduced 
in fecal samples derived from obese subjects compared to lean subjects (Fig. 5.6-4B). These results 
are in accord with the possibility that insufficient immune responses to flagellin contribute to low-
grade inflammation thought to promote this disorder and, consequently, that immunization with 
flagellin may be able to prevent or ameliorate this disorder. To examine this possibility, flagellin-
immunized and control PBS-treated mice were monitored following administration of an 
obesigenic high-fat diet (HFD). We observed that flagellin-immunized mice gained less weight 
and exhibited less adiposity compared with non-immunized animals (Fig. 5.6-4C-D). Moreover, 
flagellin immunization was associated with decreased intestinal inflammation, as revealed by a 
protection against colon shortening and spleen enlargement that normally result from a WSD 
treatment (Fig. 5.6-4E-F). Correlation analysis revealed that fecal anti-flagellin IgA load correlate 
with the degree of protection observed against adiposity and inflammation (Fig. 5.6-4G-I). 
Altogether, these results suggest that immunization can protect mice against low-grade 
inflammation and increased adiposity associated with a HFD regimen. 
 
5.5 Discussion 
An array of chronic inflammatory diseases, including IBD and metabolic syndrome, are 
associated with alterations in gut microbiota composition167-170. That transplants of these disease-
associated microbiotas can recapitulate many disease features in recipient mice indicates that such 
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alterations play a role in driving these inflammatory diseases151, 171, 172. While, across different 
studies, there is high variance in the specific bacterial species whose enrichment and/or depletion 
is associated with disease, one general microbiota feature, common to numerous sequence-based 
studies in mice and humans, is enrichment of flagellated bacteria. Increases in flagellated bacteria 
can result from increases in Gamma-Proteobacteria, including motile pathobiont Escherichia coli 
strains98, 153, but can also result from other classes of bacteria, especially Firmicutes, upregulating 
motility-related gene expression 57. In accord, functional-based microbiotas assessments reveal 
that these disease-associated microbiotas express high levels of flagellin and, concomitantly, have 
a high capacity to penetrate the mucus layer of their host81, 82, 148. We hypothesize that these 
encroaching bacteria play an outsize role in inducing the pro-inflammatory gene expression 
characteristic of gut inflammation. While the intestine possesses a number of innate immune 
mechanisms to keep the inner mucus layer free of bacteria, several observations suggest that 
adaptive immunity, in particular mucosal production of flagellin-specific IgA, also plays a key role 
in keeping motile bacteria in check. For example, in mice, absence of flagellin-specific IgA, due 
to absence of TLR5-mediated promotion of adaptive immunity, resulted in increased levels of 
flagellin and microbiota encroachment57. Moreover, as shown herein, relative to healthy humans, 
overweight and obese persons exhibited decreased levels of flagellin-specific IgA and increased 
levels of fecal flagellin.  
These results support the notion that natural acquisition of flagellin-specific IgA protects 
against chronic inflammatory diseases, thus leading to the suggestion that eliciting anti-flagellin 
antibodies via immunization might be a means to vaccinate against such diseases. While some 
antibodies to bacterial flagella are highly species-specific thus providing the basis for H-serotyping 
that can distinguish even closely related species of E. coli, many antibodies to flagellin recognize 
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highly-conserved flagellin epitopes, such that inoculation of mice with E. coli flagellin generated 
antibodies that exhibited considerable cross reactivity with a Clostridia flagellin104, thought to be 
one target of the increased antibody response to flagellin154. Thus, even though the specific bacteria 
that might encroach upon the epithelium in various disease states have not been identified, and 
likely vary considerably in different hosts and disease states, we hypothesized that eliciting a 
robust anti-flagellin response might nonetheless provide a degree of protection across a range of 
chronic inflammatory diseases. Accordingly, as shown herein, elicitation of flagellin-specific IgA 
via exogenous administration of flagellin has potential to protect against some chronic 
inflammatory diseases, including colitis and obesity. 
Adaptive immunity to flagellin is an established feature of IBD, especially Crohn’s disease, 
in that IBD patients have elevations in serum antibodies (IgG and IgA) and a greater frequency of 
flagellin-specific CD4 T-cells77, 154, 173, 174. That transfer of flagellin-specific T-cells to immune 
deficient mice can induce colitis demonstrates potential for flagellin-specific immunity to be 
detrimental, and underscores that caution should be taken in the deliberate elicitation of flagellin-
specific immunity154. Yet, whether flagellin-targeted immune responses actually drive IBD in 
humans or are a beneficial adaptation that protects IBD patients from their microbiota is not 
known, and may in fact vary substantially depending upon the time such responses are elicited 
together with the underlying cause of disease. For example, it seems reasonable to envisage that 
persons with an innate immune deficiency, for example those with non-functional Nod2, might 
benefit from deliberate induction of adaptive immunity to flagellin, while such treatment might be 
detrimental to those with inherent immune dysregulation, such as persons with mutations in IL-23 
and/or IL-10 signaling pathways. However, that administration of flagellin to IL-10-/- mice elicited 
exaggerated antibody responses to flagellin (relative to WT mice) and reduced subsequent 
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development of colitis suggests that even hosts with inherent immune dysregulation can benefit 
from elevated immune responses to flagellin, at least if elicited prior to disease development. 
Another possibility is that flagellin-specific antibodies are beneficial, perhaps in part because they 
can exclude flagellated bacteria from the inner mucus, while activation of flagellin-specific T-
cells, which might occur as result of altered gut permeability, can drive detrimental immune 
activation. Lastly, given that we note that immune responses to flagellin are normally tightly 
compartmentalized to the mucosal compartment175, it is possible that mucosal responses to 
flagellin are beneficial while systemic responses are detrimental. While the systemic 
administration used here elicited a potent systemic response, we envisage that development of 
approaches to administer flagellin to the gut mucosal immune system, perhaps with nanoparticles 
specifically targeting the mucosa, might provide a means to preferentially elicit mucosal 
antibodies, which may prove safer and more effective.  
While numerous remaining questions highlight the need for extensive further pre-clinical 
development of using flagellin administration to vaccinate against colitis, we nonetheless submit 
that our results herein demonstrate the potential for this approach to prevent gut inflammation. 
Indeed, should elicitation of flagellin-specific mucosal antibodies keep motile bacteria in check, 
prevent microbiota encroachment, and result in a generally less pro-inflammatory microbiota in 
humans, we submit this approach may reduce development of a broad array of inflammatory 
diseases including IBD, metabolic syndrome, and perhaps colon cancer. Indeed, we note that 
bacteria that have been proposed to promote colon cancer, including E. coli and B. fragilis, are 
often flagellated. Thus, caveats notwithstanding, we submit that administration of flagellin has 
potential to vaccinate against an array of diseases associated with, and driven by, gut inflammation. 
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5.6 Figures and Legends 
 
Figure 5.6-1. Systemic flagellin administrations elicit systemic and mucosal antibodies 
to flagellin. 
(A) 4-week old C57BL/6J mice, wildtype (WT) and TLR5/NLRC4 DKO (DKO), were 
purchased from The Jackson Laboratory and housed for two weeks before procedure in order to 
favor microbiota stabilization. Subsequently, flagellin (10 µg per mouse) was administered by 
intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). Serum 
collection occurred on days -14, 0, 28, 56, and 63. Body weight measurements and fecal collection 
occurred prior to every flagellin administration. (B-C) Serum anti-flagellin IgA and IgG 
throughout the experiment, (D-E) fecal anti-flagellin IgA and IgG, (F-G) serum anti-flagellin IgA 
and IgG at day 56, (H) serum interleukin-6, and (I) CXCL1 at day 56 were analyzed using ELISA 
kits. Data are the means +/- S.E.M.. Significance was determined using t-test (*p≤0.05 **p≤0.01 
***p≤0.001, n.s. indicates non-significant). (N=4-5 mice from one out of three representative 
experiment). 
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Figure 1. Systemic flagellin administrations elicit systemic and mucosal antibodies to 
flagellin.
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Figure 5.6-2. Flagellin administration alters the intestinal microbiota towards a lower 
pro-inflammatory state. 
4-week old C57BL/6J WT mice were purchased from The Jackson Laboratory and housed 
for two weeks before procedure in order to favor microbiota stabilization. Subsequently, flagellin 
(10 µg per mouse) was administered by intraperitoneal injections weekly for 9 weeks, while control 
mice received vehicle (PBS). Fecal microbiota composition was analyzed using Illumina 
sequencing of the V4 region of 16S rRNA genes. Principal coordinates analysis (PCoA) of the 
unweighted UniFrac distance matrix at (A) day -14 and (B) day 56 (post-stabilization, post-
immunization). (C) LEFSE analysis was performed in order to investigate microbiota taxa that 
were significantly altered by immunization at day 56 (post-stabilization, post-immunization). (D) 
Fecal pro-inflammatory potential was analyzed using HEK 293 cells expressing mTLR5 or mTLR4 
measuring bioactive flagellin and lipopolysaccharide, respectively. (E) Colonic myeloperoxidase 
quantification. 8-week old, wild type C57BL/6J mice received either vehicle or 10 µg of flagellin 
Figure 2: Flagellin administration alters the intestinal microbiota towards a lower pro-
inflammatory state.
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by intraperitoneal injections weekly for 9 weeks. (F-G) Microbiota localization analysis. (F) 
Confocal microscopy analysis of microbiota localization; Muc2 (green), actin (purple), bacteria 
(red), and DNA (blue). (G) Distances of closest bacteria to intestinal epithelial cells (IEC) per 
condition over 2-3 high-powered fields per mouse. In A and B, categories were compared and 
statistical significance of clustering were determined via Permanova. Data are the means +/- 
S.E.M.. Significance was determined using t-test (*p≤0.05 ****p≤0.0001, n.s. indicates non-
significant). (N=4-5 mice from one out of three representative experiment). 
 
 
Figure 5.6-3. Flagellin administrations protect against immune dysregulation-induced 
colitis. 
4-8 week-old C57BL/6J WT and µMT mice received either vehicle or 10 µg of flagellin by 
intraperitoneal injections weekly for 9 weeks. Subsequently, animals were treated weekly for 4 
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Figure 3: Flagellin administrations protect against immune dysregulation-induced colitis.
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weeks by 1 mg of anti-IL10r antibody intraperitoneally to induce intestinal inflammation. 
Biometric data of WT animal represented by (A) body weight, (B) adipose weight, (C) spleen 
weight, (D) colon weight, (E) colon length, (F) and colon weight/length ratio. (G) Colonic 
myeloperoxidase levels. (H) Colon pathohistological scoring. (I-J) Serum interleukin-6 and 
CXCL1. (K) Severity of colitis in µMT animal represented by colon length. (L-N) Principal 
coordinate analysis of the Bray-Curtis distance using a matrice containing all the morphometric 
and molecular parameters presented in A-L. Data are the means +/- S.E.M.. Significance was 
determined using t-test (*p≤0.05 **p≤0.01 ****p≤0.0001, n.s. indicates non-significant) or one-
way ANOVA (#p≤0.05 ##p≤0.01 ###p≤0.001 ####p≤0.0001). (N=4-5 mice from one out of two 
representative experiment). 
 
 
Figure 5.6-4. Flagellin immunization protected against high-fat diet-induced obesity. 
(A) Flagellin load (y-axis) inversely correlate with anti-flagellin IgA concentration (x-axis) 
in humans. R2 represents the coefficient of determination. (B) Mean concentration ± s.e. of 
flagellin load and anti-flagellin IgA concentration for human subjects segregated by their BMI to 
normal (18.5-24.9, N=17), overweight (25-29.9, N=11) or obese (>30, N=15). Flagellin 
concentration is denoted on the left y-axis and anti-flagellin IgA concentration is denoted on the 
right y-axis. *P < 0.05; one-way analysis of variance (ANOVA). (C-I) 8-week old, C57BL/6J mice 
were purchased from The Jackson Laboratory and housed for two weeks before procedure in order 
to favor microbiota stabilization. Subsequently, flagellin (10 µg per mouse) was administered by 
intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). 
Subsequently, animals were treated with high-fat diet (60% kcal from fat) for 4 weeks. (C) Body 
weights were measured weekly and expressed as relative values, day 63 (post-immunization, pre 
high-fat diet treatment) being define as 100%. (D) Adipose weight. (E) Colon length. (F) Spleen 
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Figure 4: Flagellin immunization protected against high-fat diet-induced obesity.
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weight. (G-I) Day 63 fecal anti-flagellin IgA correlated with adipose and spleen weights, as well 
as, colon length. Data are the means +/- S.E.M.. Significance was determined using one-way 
ANOVA (#p≤0.05 ##p≤0.01). (N=4-5 mice from one out of two representative experiment). 
 
5.7 Supplemental Figures and Legends 
 
Figure 5.7-1. LEFsE and histopathological analysis in flagellin immunized vs. non-
immunized mice. 
4-week old C57BL/6J mice were immunized with flagellin (10 µg per mouse) by 
intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). (A) 
LEFsE analysis at day 56 reveals multiple bacterial groups altered by flagellin immunization 
compared to PBS treated mice. 6 week-old C57BL/6J WT mice received either vehicle or 10 µg of 
flagellin by intraperitoneal injections weekly for 9 weeks. Subsequently, animals were treated 
weekly for 4 weeks by 1 mg of anti-IL10r antibody intraperitoneally to induce intestinal 
inflammation. Mice were euthanized and hematoxylin & eosin staining was performed on colonic 
sections. (B) Representative images were selected from 1 animal per cage.  
  
Figure S1: LEFsE and histopathological analysis in flagellin immunized vs. non-immunized 
mice.
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Figure 5.7-2. Flagellin immunization protects against spontaneous colitis in IL10KO 
mice 
6-8 week-old, IL10KO mice received either vehicle or 10 µg of flagellin by intraperitoneal 
injections weekly for 17 weeks. Mice were subsequently euthanized and colon length were 
measured. (A-B) Fecal anti-flagellin IgA and IgG. (C-D) Day 112 serum anti-flagellin IgA and 
IgG. (E) Body weights were measured weekly and expressed as relative values, day 0 being define 
as 100%. (F) Spleen weight. (G) Colon length. (H) Colon weight/length ratio. (I) Colonic 
myeloperoxidase levels. (J-L) Correlation of colon length from IL10KO mice and Day 112 fecal 
IgA and IgG, and Day 112 serum IgA. Data are the means +/- S.E.M.. Significance was determined 
using t-test (*p≤0.05 **p≤0.01 ****p≤0.0001). (N=9-13). 
 
Figure S2: Flagellin immunization protects against spontaneous colitis in ILKO mice.  
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Figure 5.7-3. Flagellin shows repeated protection against anti-IL 10r treatment but does 
not confer protection against DSS induced acute intestinal inflammation. 
8-week old, wild type C57BL/6J mice were purchased from The Jackson Laboratory and 
housed for two weeks before procedure in order to favor microbiota stabilization. Subsequently, 
flagellin (10 µg per mouse) was administered by intraperitoneal injections weekly for 9 weeks, 
while control mice received vehicle (PBS). Subsequently, colitis was induced by either 4 weekly 
intraperitoneal injections of 1 mg anti-IL10r antibody or by treatment with DSS diluted in the 
drinking water (2.5%). Body weights were measured weekly and expressed as relative values, (A) 
day -14 (pre-immunization) or (B-C) day 63 (post-immunization, pre-colitis induction) being 
define as 100%. (D) Spleen weight. (E) Colon length. Data are the means +/- S.E.M.. Significance 
was determined using t-test (*p≤0.05 **p≤0.01). (N=4-5). 
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Figure S3: Flagellin shows repeated protection against anti-IL 10r treatment, but does not 
confer protection against DSS induced acute intestinal inflammation.
Control DSS aIL-10R-Ab
0
50
100
150
200
Spleen weight
m
ill
ig
ra
m
s
Control DSS aIL-10R-Ab
4
6
8
10
12
Colon length
ce
nt
im
et
er
s
**
63 70 77 84
85
90
95
100
aIL-10R-Ab weight
Day
%
 b
od
y 
w
ei
gh
t
a
-IL
10
r-A
b
PBS/aIL-10R-Ab
FliC/aIL-10R-Ab
#
63 65 67 71 73
65
75
85
95
105
DSS weight
Day
%
 b
od
y 
w
ei
gh
t
DS
S
PBS/DSS
FliC/DSS
-14 0 14 28 42 56 70
90
100
110
120
130
140
DSS weight
Day
%
 b
od
y 
w
ei
gh
t
DS
SPBS/DSS
FliC/DSS
WT + PBS
WT + FliC
WT + PBS/DSS
WT + FliC/DSS
WT + PBS/αIL-10R-Ab
WT + FliC/ αIL-10R-Ab
A B
D E
C
106 
5.8.3 Funding.  
This work was supported by NIH grant DK099071 (A.T.G.) and DK083890 (A.T.G.). B.C. 
is a recipient of the Career Development Award from the Crohn’s and Colitis Foundation and an 
Innovator Award from the Kenneth Rainin Foundation. 
 
5.8.4 Authors’ contributions 
Conception and design: H.Q.T., A.T.G, B.C.. Development of methodology: H.Q.T., 
A.T.G, B.C.. Acquisition of data: H.Q.T., B.C.. Analysis and interpretation of data: H.Q.T., A.T.G, 
B.C.. Writing, review, and/or revision of the manuscript: H.Q.T., A.T.G, B.C.. 
  
107 
6 CONCLUSIONS 
The overall goal of this study was to investigate the role of the intestinal microbiota in its 
interaction with the host immune system and its causation and exacerbation of metabolic syndrome 
through 3 independent, but interrelated Specific Aims.  
 
6.1 Specific Aim 1 Conclusions: Microbial determinants of obesity. 
The goal of this aim was to improve understanding of non-genetic determinants of obesity, 
with a focus on parameters impacted by gut microbiota. I initially hypothesized that inflammatory 
and microbial factors might impact behavior and/or metabolism and thereby predict the extent of 
DIO displayed by individual hosts. Results show that behavioral measures were not predictive of 
susceptibility to HFD-induced obesity while inflammatory markers showed only very limited 
ability in predicting obesity. In the investigation of the involvement of LPS and flagellin in 
inflammation and obesity, measured flagellin levels showed promise for predicting weight after 
administration of HFD, it was less successful prior to administration. These results revealed new 
evidence of host-microbial interactions underlying differential weight gain. 
Results from untargeted metaproteomic analyses shows large shifts in the overall structure 
of the metaproteome after administering HFD in concordant with prior research93. These broad 
shifts seem to be driven by proteins derived from Clostridiales and Bacteroidales, however, this 
difference was not observable in our analysis of the microbiota by 16S sequencing, possibly due 
to the known discrepancy between genomic and proteomic technologies95.  
Functionally, the most remarkable shift with DIO was the decrease of flagella after 
administration of HFD. Flagellin proteins can be targeted in several ways by the host, including 
the release of anti-flagellin IgA and IgG as a key mechanism for down regulating motility-related 
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genes57. While the overall levels of anti-flagellin IgG and IgA in general did not significantly 
correlate with the obesogenic outcomes, results showed a distinct immune signature within the 
fecal proteome of the high responder mice. This data may suggest that the mice that gain the most 
weight have a baseline immune reaction occurring before treatment. Possible antigens of this 
immune reaction were also identified from the metaproteome data including a subset of flagellin 
proteins that effectively discriminate high and low responders.  
In total, this work suggests the ability of host and microbial proteomics to discern subjects 
particularly prone to developing DIO. My results indicated significant metaproteomic differences 
between differential responses to HFD. In addition, the taxonomic origins and functional roles of 
these discriminatory proteins suggested new evidence that host-microbiota interactions may be 
underlying proneness to DIO.  
 
6.2 Specific Aim 2 Conclusions: The role of the microbiota in driving adipose 
inflammation. 
Inflammation of visceral adipose tissue is a central link between obesity and metabolic 
syndrome. That adipose inflammation and parameters of metabolic syndrome can be induced by 
transplant of microbiota with pro-inflammatory features99 or direct administration of LPS100. 
indicate that microbiota is a plausible determinant of adipose inflammation. Hence, the central 
goal of this aim was to investigate the extent to which gut microbiota was necessary for the low-
grade inflammation, induced by a western-style high-fat diet. Utilizing various approaches of 
ablating microbiota, all of which yielded a similar pattern of results, namely that, microbiota 
played a critical role in adipose inflammation and, consequently, features of metabolic syndrome. 
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Relative to mice fed grain-based chow, WSD induces rapid reduction of colonic bacterial 
density and marked changes in species composition, which is proposed to drive inflammation and 
dysglycemia129. Additionally, more traditional markers of inflammation such as elevations in 
serum cytokines, and leukocyte infiltration have generally been reported in response to longer-
term WSD feeding. Some metabolic consequences of WSD occur quite rapidly with dysglycemia 
being present within days of exposure to WSD although robust development of metabolic 
syndrome, including more severe insulin resistance requires longer-term exposure to WSD130. 
Genetic approaches that seek to block leukocyte activation indicate that inflammation is 
dispensable for the rapid changes but critical for long-term insulin resistance130. Thus, I conclude 
that ablation of microbiota protects against adipose inflammation, which is a key driver of 
metabolic syndrome.   
That absence of MyD88, which is necessary for generation of pro-inflammatory signaling, 
fully mimicked the protection against adipose inflammation that resulted from microbiota ablation 
suggests a role for bacterial products in driving adipose inflammation. The combination of 
microbiota encroachment amidst reduced gut barrier function in response to WSD can be 
envisaged to result in bacterial products or perhaps even bacteria reaching the visceral adipose 
tissue. Results of ASF mice showing protection against WSD-induced adipose inflammation, and 
its associated metabolic consequences, highlights that microbiota composition, rather than the 
mere presence of bacteria in the gut is a determinant of susceptibility to WSD.  
In conclusion, these findings indicate that the mechanism by which WSD-induced obesity 
results in adipose inflammation is dependent on the intestinal microbiota, possibly reflecting a 
deterioration in intestinal-microbiota homeostasis that results in activation of innate immune 
signaling. Should such events occur in humans, they might, in part, be a basis for why some obese 
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persons remain relatively metabolically healthy while others develop metabolic. Moreover, my 
study hypothesizes that restoration of a host-microbiota homeostasis through diet, pharmacologic, 
and/or perhaps pre/pro-biotic approaches might be a means to alleviate visceral adipose tissue 
inflammation and its metabolic consequences.  
 
6.3 Specific Aim 3 Conclusions: A novel strategy to prevent bacterial translocation and 
subsequent disease. 
An array of chronic inflammatory diseases, including IBD and metabolic syndrome, are 
associated with alterations in gut microbiota composition167-170. One general microbiota feature, 
common to numerous sequence-based studies in mice and humans, is the enrichment of flagellated 
bacteria. Functional-based microbiotas assessments reveal that these disease-associated 
microbiotas express high levels of flagellin and, concomitantly, have a high capacity to penetrate 
the mucus layer of their host81, 82, 148. We hypothesize that these encroaching bacteria play a vital 
role in inducing the pro-inflammatory gene expression characteristic of gut inflammation. While 
the intestine possesses a number of innate immune mechanisms to keep the inner mucus layer free 
of bacteria, several observations suggest that mucosal production of flagellin-specific IgA, also 
plays a key role in keeping motile bacteria in check. Moreover, we show that relative to healthy 
humans, overweight and obese persons exhibited decreased levels of flagellin-specific IgA and 
increased levels of fecal flagellin.  
These results support the notion that natural acquisition of flagellin-specific IgA protects 
against chronic inflammatory diseases, thus leading to the suggestion that eliciting anti-flagellin 
antibodies via immunization might be a means to vaccinate against such diseases. Though the 
specific bacteria that might encroach upon the epithelium in various disease states have not been 
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identified, we hypothesized that eliciting a robust anti-flagellin response might nonetheless 
provide a degree of protection across a range of chronic inflammatory diseases. Accordingly, as 
shown, elicitation of flagellin-specific IgA via exogenous administration of flagellin has potential 
to protect against some chronic inflammatory diseases, including colitis and obesity. 
These results demonstrate the potential for flagellin administration to prevent gut 
inflammation. Indeed, should elicitation of flagellin-specific mucosal antibodies keep motile 
bacteria in check, prevent microbiota encroachment, and result in a generally less pro-
inflammatory microbiota in humans, this approach may reduce development of a broad array of 
diseases associated with, and driven by, gut inflammation. 
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